UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-KSB
                                   (Mark One)

|X|   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005

                                       OR

|_|   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____TO _______

                        COMMISSION FILE NUMBER: 33-43423

                               NUWAY MEDICAL, INC.
                 (Name of Small Business Issuer in its Charter)

              Delaware                                   65-0159115
  (State or other jurisdiction of             (IRS Employer Identification No.)
   incorporation or organization)

                 2603 Main Street, Suite 1155, Irvine, CA 92614
               (Address of principal executive offices, Zip Code)

         Issuer's telephone number, including area code: (949) 235-8062

       Securities registered under Section 12(b) of the Exchange Act: None

         Securities registered under Section 12(g) of the Exchange Act:
                        Common Stock, $0.00067 par value

      Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the Registrant was required to file such reports), and (2)
been subject to such filing requirements for the past 90 days. Yes |X| No |_|

      Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of Registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB |_|.

      Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes |X| No |_|

      Issuer's revenue for its most recent fiscal year: $ -0-

      The aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of March
30, 2006 was $903,590

                                       1
<PAGE>

      The number of shares outstanding of the issuer's class of common equity as
of March 30, 2006 was 62,453,501.

      Transitional Small Business Disclosure Format (check one): Yes |_| No |X|




                                       2
<PAGE>

                                TABLE OF CONTENTS

PART I
     Item 1. Description of Business                                           4
     -------------------------------
     Item 2. Description of Property                                          12
     -------------------------------
     Item 3. Legal Proceedings                                                12
     -------------------------
     Item 4. Submission of Matters to a Vote of Security Holders              13
     -----------------------------------------------------------

PART II
     Item 5. Market for Common Equity and Related Stockholders Matters        14
     -----------------------------------------------------------------
     Item 6. Management's Discussion and Analysis of Financial Condition
     and Results of                                                           17
     ------------------------------------------------------------------------
     Operation
     ---------
     Item 7. Financial Statements                                             26
     ----------------------------
     Item 8. Changes In and Disagreements with Accountants on Accounting
     and Financial                                                            26
     ------------------------------------------------------------------------
     Disclosure
     ----------
     Item 8A. Controls and Procedures                                         26
     --------------------------------
     Item 8B. Other Information                                               27
     --------------------------

PART III
     Item 9. Directors, Executive Officers, Promoters and Control
     Persons; Compliance with                                                 28
     ------------------------------------------------------------------------
     Section 16(a) of the Exchange Act
     ---------------------------------
     Item 10. Executive Compensation                                          28
     -------------------------------
     Item 11. Security Ownership of Certain Beneficial Owners and Management  28
     -----------------------------------------------------------------------
     Item 12. Certain Relationships and Related Transactions                  28
     -------------------------------------------------------
     Item 13. Exhibits                                                        28
     -----------------
     Item 14. Principal Accountant Fees and Services                          31
     -----------------------------------------------
     Signatures                                                               32
     ----------
     Index to Financial Statements                                           F-1
     -----------------------------
     Report of Independent Registered Public Accounting Firm                 F-2
     -------------------------------------------------------
     Consolidated Financial Statements for the Years Ended
     December 31, 2004 and 2003                                              F-3
     ---------------------------------------------------------------------------
     Exhibits Filed With This Report
     -------------------------------







                                       3
<PAGE>

                                     PART I

ITEM 1. DESCRIPTION OF BUSINESS

USE OF FORWARD LOOKING STATEMENTS IN THIS REPORT

      This Annual Report on Form 10-KSB (the "Annual Report") contains
forward-looking statements. These forward-looking statements include predictions
regarding our future:

            obusiness and acquisition plans;
            ofinancing plans;
            ogeneral and administrative expenses;
            oliquidity and sufficiency of existing cash;
            othe outcome of pending or threatened litigation; and
            othe effect of recent accounting pronouncements on our financial
             condition and results of
            operations.

      You can identify these and other forward-looking statements by the use of
words such as "may," "will," "expects," "anticipates," "believes," "estimates,"
"continues," or the negative of such terms, or other comparable terminology.
Forward-looking statements also include the assumptions underlying or relating
to any of the foregoing statements.

      Our actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors, including those set
forth below under the heading "Risk Factors." All forward-looking statements
included in this document are based on information available to us on the date
hereof. We assume no obligation to update any forward-looking statements.

      The information contained in this Annual Report is as of December 31,
2005, unless expressly stated otherwise.

OVERVIEW

      NuWay Medical, Inc., a Delaware corporation (the "Company"), had no
continuing business operations as of December 31, 2005. At this time, the
Company is operating as a public shell and management is actively seeking merger
and acquisition candidates with ongoing operations. Over the course of the last
several years, the Company had attempted to enter various businesses through the
acquisitions of entities operating ongoing businesses or technology that needed
to be developed and marketed. However, as a result of various factors, primarily
inadequate capital and the inability to raise sufficient financing successfully,
these acquisitions could not be properly exploited and integrated to produce
profitable operations by the Company and management disposed of, or abandoned,
these other acquisitions.

      The Company has identified an acquisition candidate, IOWC Technologies,
Inc. ("IOWC"), the owner, along with Kenneth Reay Code (Mr. Code and IOWC are
collectively referred to herein as "BioLargo"), of certain technology referred
to herein as the "BioLargo Technology". As described below, the Company and
BioLargo have entered into a Marketing and Licensing Agreement (the "M&L
Agreement") and the Company intends to acquire substantially all of the assets
of IOWC, subject to various conditions, including approval of the Company's
stockholders.

                                       4
<PAGE>

      Recently, the Company has struggled to deal with the following issues,
often simultaneously:

      o     Limited capital resources in a prolonged period of difficulty in the
            capital markets, especially for small public companies, creating
            severe limitations on the Company's ability to maintain its
            reporting obligations under the Securities Exchange Act of 1934, as
            amended (the "Exchange Act"), and its business operations

      o     Trying to acquire or develop new businesses

      o     Because of the scarcity of cash on hand, using common stock and
            securities convertible into common stock to bring on board
            employees, directors, consultants, professional service provides and
            advisors

      o     Because of the scarcity of cash on hand, using common stock and
            securities convertible into common stock to acquire businesses

      o     Dealing with inquiries from the Securities and Exchange Commission
            (the "SEC") regarding certain practices and transactions in the
            Company's past, including questions raised about any continued
            involvement of Mark Roy Anderson in the ongoing business of the
            Company

      o     Dealing with inquiries from the Federal Bureau of Investigation
            ("FBI") related to any past dealings with Mr. Anderson or his
            affiliates

      o     Dealing with litigation with former officers of the Company and
            related litigation stemming from their leadership of the Company

      These issues continue to present extraordinary challenges to management as
it tries slowly to turn the situation around. The Company is presently focused
primarily on maintaining the corporate entity, complying with its reporting
obligations under the Exchange Act and actively seeking new business
opportunities. The Company will need working capital resources to maintain the
Company's status and satisfy its reporting obligations, and to fund other
anticipated costs and expenses during the year ending December 31, 2006 and
beyond, especially if the transactions with BioLargo are consummated. The
Company's ability to continue as a going concern is dependent on the Company's
ability to raise capital to, at a minimum, meet its corporate maintenance
requirements and reporting obligations. If the Company is able to acquire
BioLargo or another ongoing business and/or technology that must be exploited,
the Company would need additional capital until and unless that prospective
operation is able to generate positive working capital sufficient to fund the
Company's cash flow requirements form operations.

      The Company was initially organized as Repossession Auction, Inc. under
the laws of the State of Florida in 1989. In 1991, the Company merged into a
Delaware corporation bearing the same name. In 1994, the Company's name was
changed to Latin American Casinos, Inc. to reflect its focus on the gaming and
casino business in South and Central America, and in 2001 the Company changed
its name to NuWay Energy, Inc. to reflect its new emphasis on the oil and gas
development industry. During October 2002, the Company's name was changed to
NuWay Medical, Inc. coincident with the divestiture of its non-medical assets
and the retention of new management.

      PROPOSED ACQUISITION OF IOWC

      On July 25, 2005, the Company executed a letter of intent ("LOI") with
IOWC, pursuant to which the Company will acquire certain of BioLargo's assets
(the "Purchased Assets"), consisting of certain intellectual property, including
two United States patents (collectively, the "BioLargo Technology"), and two
license and/or distributor agreements pursuant to which IOWC has licensed the
BioLargo Technology for use in products designed for distribution in the food,
medical and biohazardous material transportation industries. All assets not
constituting the Purchased Assets will remain the property of BioLargo following
the closing. The Company will not assume any liabilities of BioLargo.

                                       5
<PAGE>

      The parties also agreed that on or prior to the closing, they would enter
into a definitive asset purchase agreement (the "Asset Purchase Agreement"), and
other agreements, including a research and development agreement (the "R&D
Agreement"), to effect the transactions (the "Transactions") on or prior to the
closing. Pursuant to the R&D Agreement, the Company will pay BioLargo a monthly
fee to conduct research to further develop the existing BioLargo Technology and
products based on the existing and new technologies.

      The LOI also requires the Company to raise sufficient funds to (i) cover
the costs of the transactions, (ii) three months post-closing operating
expenses, the latter of which is estimated at approximately $300,000 and (iii)
provide interim funding to BioLargo on a best efforts basis and in amounts
agreed between the parties in an aggregate amount not to exceed $1,000,000.

      The LOI further provides that, at the Closing, the Company and Dennis
Calvert will enter into an employment agreement for a term of five years,
providing Mr. Calvert with a monthly salary of $15,400 for 2006, and a 10%
increase in his monthly salary for each calendar year thereafter.

      It is anticipated that the present management of the Company will remain
in place after the closing and that Mr. Code will become the Company's Chief
Technology Officer. In connection therewith, Mr. Code will enter into an
employment agreement with the Company (the "Code Employment Agreement").

      In connection with the previously described transactions and in partial
implementation thereof, on December 31, 2005, the Company executed the M&L
Agreement with BioLargo. Pursuant to the M&L Agreement, the Company, through its
wholly-owned subsidiary BioLargo Life Technologies, Inc., a California
corporation ("BLTI"), has the right ("Rights") to develop, market, sell and
distribute products that were developed, and are in development, by BioLargo
using the BioLargo Technology.

      BioLargo also assigned to BLTI its rights and obligations under two
license agreements, including BioLargo, LLC, in which BioLargo has a 20%
interest, as well as its rights set forth in a LOI with another entity
(collectively, the "Assigned Agreements"). The M&L Agreement provides that the
Company is to receive any and all royalties, payments, license fees, and other
consideration generated by the Assigned Agreements. As part of the M&L
Agreement, IOWC has agreed to transfer its 20% interest in BioLargo, LLC to the
Company. In consideration of the Rights and the Assigned Agreements, the Company
has agreed to issue IOWC a total of 38% of its common stock.

      The parties further agreed to enter into additional agreements in
furtherance of the July 2005 LOI between the Company and IOWC, including (i) the
Asset Purchase Agreement, whereby the Company would acquire the two U.S. patents
held by IOWC; (ii) the R&D Agreement, with a company to be managed and
controlled by Mr. Code; and (iii) the Code Employment Agreement. In
consideration of the Asset Purchase Agreement, the Company has agreed to issue
IOWC an additional one percent of its common stock. In consideration of the R&D
Agreement and Code Employment Agreement, the Company has agreed to issue to Code
individually 17.6% of its common stock. As a result of the foregoing
transactions, the Company will issue a total of 56.6% of its common stock to
BioLargo, calculated on January 1, 2006. The parties further agreed that to the
extent that the Company issues additional equity in connection with one or more
financing transactions after January 1, 2006, then the percentage of equity to
be issued to BioLargo would be diluted pro rata.

      The Code Employment Agreement is anticipated to provide that Mr. Code will
be appointed Chief Technology Officer of BLTI, and receive a monthly salary of
$15,400. As explained below, the Company is required to obtain the approval of
its stockholders prior to the issuance of the common stock to IOWC required
pursuant to the M&L Agreement.

      The foregoing transactions are subject to approval by IOWC's board of
directors and stockholders, approval by the Company's board of directors, and
approval by the Company's stockholders of the following matters:

                                       6
<PAGE>

      o     an amendment to the Company's Certificate of Incorporation
            increasing the number of authorized shares of its common stock;
      o     the issuance of the number of shares of common stock to IOWC
            required pursuant to the Transactions;
      o     a reverse split of the Company's common stock; and
      o     theelection of Mr. Code to the Company's board of directors.

      In the event that the Company's stockholders do not approve the issuance
of stock, the M&L Agreement shall terminate, and all rights granted to the
Company shall revert to BioLargo.

      The closing of the transactions is subject to various conditions,
including those described hereinabove, and conditions customary for transactions
of this nature.

EMPLOYEES

      At December 31, 2005, the Company employed one full-time employee,
reflecting the reduced operations of the Company at that time.

RISK FACTORS

      The Company faces a number of significant risks associated with its
current plan of operations. These include the following:

      WE HAVE A LIMITED OPERATING HISTORY AND A HISTORY OF LOSSES.

      The Company has no current operations and, as such, may not be able to
overcome unanticipated difficulties that may be encountered related to the
implementation of its business plan. The Company has a limited operating
history, limited revenue from operations and a history of losses. In addition,
because the Company currently has no operations, the Company faces all of the
risks inherent with a start-up business, including the possibility that the
Company cannot acquire or develop a business that is viable. There is no
assurance that, if the Company does find or develop a business, to acquire,
whether such business will ever be profitable. The Company may also face
unforeseen problems, difficulties, expenses or delays in implementing its
business plan.

      WE NEED ADDITIONAL FUNDS TO MAINTAIN AND DEVELOP OUR BUSINESS.

      If it necessary for the Company to seek to secure additional funds for any
new business, general and administrative expenses and period reporting
requirements, there can be no assurance that such funds will be available, or
will be available on favorable terms. Failure to secure needed funds will
directly impact the Company's ability to maintain its publicly-traded status
and, potentially, the corporate entity itself. While management has dedicated
itself to the efforts to secure needed funds, the outcome and ultimate success
of those efforts is uncertain.

      THE COST OF MAINTAINING OUR REPORTING OBLIGATIONS IS HIGH.

      The Company is obligated to maintain its periodic public filings and
public reporting requirements, on a timely basis, under the Rules and
Regulations of the SEC. In order to meet these obligations, the Company will
need to continue to raise capital. If adequate funds are not available to the
Company, it will be unable to comply with those requirements and could cease to
be qualified to have its stock traded in the public market.


                                       7
<PAGE>

      WE HAVE SUBSTANTIAL DEBT OBLIGATIONS MATURING DURING 2006.

      We have approximately $2,740,570 aggregate principal amount of our
promissory notes that mature at various times during 2006. We do not presently
have funds sufficient to repay these obligations as they mature. Even though the
terms of all of these notes permit the noteholder to convert the notes into
shares of our common stock, until our stockholders approve an amendment to the
Company's charter to increase the number of authorized shares of common stock,
the Company will be unable to fulfill its obligations to all noteholders to
permit the conversion into common stock of amounts due pursuant to the terms of
the notes. In the event that the Company has not raised further capital prior to
the maturity dates of the convertible notes, the Company would be in default of
those notes if its stockholders have not formally approved an increase in the
number of authorized common shares, or unless the Company is able to refinance
or renegotiate the terms of these notes. No financing is in place at present,
and it is unknown if any financing will be in place in the future, which would
permit the Company to repay these notes in full as they mature.

      OUR STOCKHOLDERS FACE POTENTIAL DILUTION IN ANY NEW FINANCING.

      Any additional equity that the Company raises would dilute the interest of
the current stockholders and any persons who may become stockholders before such
financing. Given the low price of the Company's common stock, such dilution in
any financing of a meaningful amount, could be substantial.

      OUR STOCKHOLDERS FACE POTENTIAL ADVERSE EFFECT FROM THE TERMS OF ANY NEWLY
      ISSUED PREFERRED STOCK.

      In order to raise capital to meet expenses or to acquire a business, the
Board of Directors of the Company may issue additional stock, including
preferred stock. Any preferred stock which the Company may issue may have voting
rights, liquidation preferences, redemption rights and other rights, preferences
and privileges. The rights of the holder's of the Company's Common Stock will be
subject to, and in many respect subordinate to, the rights of the holders of any
such preferred stock. Furthermore, such Preferred Stock may have other rights,
including economic rights, senior to the Company's Common Stock that could have
a material adverse effect on the value of the Company's Common Stock. Preferred
stock, while providing desirable flexibility in connection with possible
acquisitions and other corporate purposes, can also have the effect of making it
more difficult for a third party to acquire a majority of outstanding voting
stock of the Company, thereby delaying, deferring or preventing a change in
control of the Company.

      THE TRANSACTIONS WITH IOWC REQUIRE STOCKHOLDER APPROVAL. WE HAVE BEEN
      UNABLE TO OBTAIN A QUORUM AND SCHEDULE A VOTE OF STOCKHOLDERS TO APPROVE
      CERTAIN MATERIAL TRANSACTIONS IN THE PAST.

      The Company will be required to obtain stockholder approval to approve the
transactions with BioLargo; and amend its charter to increase the authorized
number of shares to approve a transaction with New Millennium Capital Partners,
LLC ("New Millennium"), which is controlled by our CEO and President Dennis
Calvert; raise funds; or effect a conversion of the convertible notes beyond the
number of shares of common stock currently authorized but unissued. Obtaining
stockholder approval is both costly and uncertain as to its success. The Company
has attempted to secure stockholder votes for certain corporate actions in the
past and has been unable to secure a quorum. As a result, the Company has been
unable to effect certain material transactions, and this inability to act could
threaten the viability of the Company. If the Company is unable to obtain the
necessary stockholder approval of the transactions with BioLargo, the M&L
Agreement will terminate and all rights granted by BioLargo to the Company will
revert to BioLargo. In addition, the inability of the Company to obtain
stockholder approval of various additional contemplated transactions, could have
an adverse affect on the Company's ability to recapitalize, restructure its
debts, obtain funding and execute its business plan, among other things.

      IF WE ACQUIRE A BUSINESS, WE WILL BE DEPENDENT UPON MARKET ACCEPTANCE AND
      COMPETITIVE FACTORS.

      The success of any business, such as IOWC, which the Company acquires, or
develops, will be highly dependent upon, among other things, gaining market
acceptance from customers that will use the company's products and services.
More specifically, these factors include, among other things, how well its
products or services perform (ease of implementation, ease of use by customers,
reliability, and scope of products and services), competitive forces, the level
of consumer demand for products and services offered, the selling prices of its
products and services, and the effectiveness of the Company's marketing
activities.

                                       8
<PAGE>

      IF WE CONSUMMATE THE TRANSACTIONS WITH BIOLARGO, THERE WILL BE A CHANGE OF
      CONTROL OF THE COMPANY.

      If our stockholders approve the transactions with BioLargo and the
transactions are subsequently consummated, the Company will issue an aggregate
of 56.6% of its common stock to BioLargo, which amount is subject to adjustment
downward under certain circumstances. This change of control could have certain
consequences for the Company, including, without limitation, a change in control
of the Company's Board of Directors and the ability of BioLargo to direct the
outcome of many matters on which the Company's stockholders are entitled to vote
in the future.

      OUR COMMON STOCK IS THINLY TRADED AND LARGELY ILLIQUID.

      In June 2003, our common stock was delisted from the NASDAQ SmallCap
Market. Our stock currently trades on the Pink Sheets. The delisting has made it
more difficult to buy or sell our stock and has lead to a significant decline in
the frequency of trades and trading volume. The delisting will likely adversely
affect the Company's ability to obtain financing in the future due to the
decreased liquidity of the Company's shares. There can be no assurance when or
if the Company's common stock will be quoted on the OTC Bulletin Board, in light
of the public interest concerns previously raised by NASDAQ in connection with
the delisting of the Company's shares.

      OUR COMMON STOCK IS SUBJECT TO "PENNY STOCK" REGULATIONS THAT MAY AFFECT
      THE LIQUIDITY FOR OUR COMMON STOCK.

      Our common stock is subject to the rules adopted by the SEC that regulate
broker-dealer practices in connection with transactions in "penny stocks." Penny
stocks are generally equity securities with a price of less than $5.00 (other
than securities registered on certain national securities exchanges or quoted on
the NASDAQ Stock Market, provided that current price and volume information with
respect to transactions in such securities is provided by the exchange or
system). The penny stock rules require a broker-dealer, prior to a transaction
in a penny stock not otherwise exempt from those rules, deliver a standardized
risk disclosure document prepared by the SEC, which contains the following:

      o     a description of the nature and level of risk in the market for
            penny stocks in both public offerings and secondary trading

      o     a description of the broker's or dealer's duties to the customer and
            of the rights and remedies available to the customer with respect to
            violation to such duties or other requirements of Securities' laws

      o     a brief, clear, narrative description of a dealer market, including
            "bid" and "ask" prices for penny stocks and significance of the
            spread between the "bid" and "ask" price

      o     a toll-free telephone number for inquiries on disciplinary actions;
            definitions of significant terms in the disclosure document or in
            the conduct of trading in penny stocks, and

      o     such other information and is in such form (including language,
            type, size and format), as the SEC shall require by rule or
            regulation.

      Prior to effecting any transaction in penny stock, the broker-dealer also
must provide the customer the following:

                                       9
<PAGE>

      o     the bid and offer quotations for the penny stock


      o     the compensation of the broker-dealer and its salesperson in the
            transaction

      o     the number of shares to which such bid and ask prices apply, or
            other comparable information relating to the depth and liquidity of
            the market for such stock

      o     the depth and liquidity of the market for such stock, and

      o     monthly account statements showing the market value of each penny
            stock held in the customer's account.

      In addition, the penny stock rules require that prior to a transaction in
a penny stock not otherwise exempt from those rules, the broker-dealer must make
a special written determination that the penny stock is a suitable investment
for the purchaser and receive the purchaser's written acknowledgment of the
receipt of a risk disclosure statement, a written agreement to transactions
involving penny stocks, and a signed and dated copy of a written suitably
statement. These disclosure requirements may have the effect of reducing the
trading activity in the secondary market for a stock such as our common stock if
it is subject to the penny stock rules.

      THE COMPANY, SOME OF ITS DIRECTORS AND ITS OFFICERS FACE RISKS IN
      CONNECTION WITH THE CRIMINAL INVESTIGATION OF A FORMER CONSULTANT AND
      PRINCIPAL STOCKHOLDER OF THE COMPANY.

      In or about May 2003, the Company learned through verbal discussions with
representatives of NASDAQ, in preparation for the Company's pending NASDAQ
qualifications hearing, that Mark Roy Anderson had a criminal background. In or
about May and June 2003, the Company was informed in writing by the United
States Attorney's office in Los Angeles, that Mr. Anderson (i) was the target of
a criminal investigation (the "Investigation") pertaining to the sale of
securities by Med Wireless, Inc. ("Med Wireless"), a which Mr. Anderson founded
and was a principal stockholder and from which the Company licensed certain
assets in 2002, and (ii) had been convicted of multiple felonies unrelated to
Med Wireless in the 1990s. Mr. Anderson was the founder and principal
stockholder of Med Wireless, and first introduced the concept of licensing the
Med Wireless software application and contracts to the Company in May 2002.

      Dennis Calvert had been approached initially by Mr. Anderson some time in
1996 to consider entering into a business consulting relationship with
Anderson-controlled entities. Over the period from 1996 to 2001, Mr. Calvert
worked as a consultant periodically with Anderson-related entities for the
purpose of evaluating potential new businesses and potential investment
opportunities being considered by Mr. Anderson and these entities. In June 2002,
Mr. Calvert agreed to become president of Med Wireless, primarily for the
purpose of completing the Med Wireless transaction with the Company. As
consideration for his agreeing to become President of Med Wireless, Mr. Calvert
received 1,327,700 shares of Med Wireless stock from Mr. Anderson's holdings.
These shares were subsequently converted into 600,000 shares of the Company's
common stock pursuant to the terms of the transaction between Med Wireless and
the Company.

      On June 28, 2002, Mr. Calvert was appointed president of the Company. At
the same time, Joseph Provenzano, who at that time was an employee of Camden
Holdings, Inc. ("Camden Holdings"), another affiliate of Mr. Anderson, joined
the Company's board of directors. In addition to the Med Wireless transaction,
entities that Mr. Anderson controls, including Camden Holdings, Genesis Health
Tech, Inc. ("Genesis"), Summit Oil & Gas, Inc. ("Summit Oil") and Casino Venture
Partners ("CVP"), invested $250,000 in the Company, sold the Company additional
assets and purchased the Company's previous operating businesses. Although Mr.
Anderson never served as an officer or director of the Company, he served as a
consultant to the Company and received consulting fees in the form of an
aggregate 1,241,884 shares of the Company's common stock. Since December 2002
Mr. Anderson has not been a consultant to the Company and since March 2003 has
not been involved in any way in the Company's operations.

                                       10
<PAGE>

      Mr. Anderson, his affiliates and New Millennium entered into a stock
purchase agreement in March 2003 (the "New Millennium Agreement"). Mr. Calvert
is the Manager and, together with his wife, the sole members of New Millennium.

      In the New Millennium Agreement, Mr. Anderson represented that he was
selling 100% of his stock to New Millennium and would no longer own any of the
Company's stock. Mr. Anderson delivered to New Millennium certificates
representing 4,182,107 shares. Subsequent to the closing of that transaction,
management learned through the Company's transfer agent that Camden Holdings
still owns 340,894 shares of the Company's common stock. The Company and New
Millennium believe that the existence of these 340,894 shares of the Company's
common stock owned by Camden Holdings is a material breach of the New Millennium
Agreement.

      Technically, under the terms of the New Millennium Agreement, it is
possible that Camden Holdings or Mr. Anderson has the right to reacquire the
shares of the Company's common stock that were sold to New Millennium, if New
Millennium defaults on the promissory note issued by New Millennium to Camden
Holdings to purchase the shares (the "New Millennium Note"). The New Millennium
Note is purportedly secured by the purchased shares of the Company's common
stock; however, New Millennium and Mr. Calvert believe that Camden Holdings and
Mr. Anderson have not perfected their security interest in those shares. New
Millennium has defaulted on the New Millennium Note. However, New Millennium
believes that Camden Holdings failed to deliver all the shares of the Company
held by Camden Holdings, and thus breached the terms of their purchase
agreement, making the New Millennium Note void by its terms. In addition,
Augustine II, LLC (the "Augustine Fund") is the pledgee of 2,500,000 of these
shares and holds those shares as pledgee.

      On or about May 17, 2003, the Company was served by a subpoena issued by
the grand jury impaneled to investigate Mr. Anderson, requesting documents
relating to Mr. Anderson and his affiliates, including Med Wireless, Camden
Holdings, Summit Oil and Summit Healthcare, Inc. ("Summit Healthcare").
Additionally, the subpoena requested information relating to the identity of the
Company's officers, directors, stockholders and consultants (legal, accounting
and otherwise), and that the Company provide copies of its filings and
correspondence with the SEC, the National Association of Securities Dealers and
the NASDAQ Stock Market. The Company cooperated fully with that request by
providing the requested information and intends to continue to fully cooperate
with any future investigative requests.

      The Company has learned that private placement memoranda distributed to
Med Wireless investors stated that Dennis Calvert was the president of Med
Wireless as early as 2001, and additionally believes that Mr. Anderson
apparently made a number of similar false representations throughout 2001 and
2002. Mr. Calvert did not approve this disclosure contained in those private
placement memoranda nor in any other form, and has informed the Company that he
was not engaged as the president of Med Wireless until June 2002 and not any
earlier, and that any statements to the contrary are untrue.

      Mr. Provenzano joined Camden Holdings in 2001 to assist in its mergers and
acquisitions department, and he worked at Camden Holdings until March 2003. Both
Mr. Calvert and Mr. Provenzano have informed both the Company and, through their
own legal counsel, the Assistant U.S. Attorney, that they intend to cooperate
fully with law enforcement officials in the Investigation.

      In mid-2003, the Company was informed by the Assistant United States
Attorney handling the Investigation that Dennis Calvert and Joseph Provenzano
were not considered "targets" of the Investigation; however, until their
respective roles, if any, in the specific events being investigated are
determined, they will be considered to be "subjects" of the Investigation,
meaning that their conduct is believed by the U.S. Attorney's office to be
"within the scope" of the grand jury's investigation.

                                       11
<PAGE>

      Although neither the Company nor any of its officers or directors is
currently the target of any criminal investigation, including the one described
in the previous paragraph, there can be no assurance that such an investigation
will not be undertaken. Additionally, although neither the Company nor its
officers or directors have been contacted by either the U.S. Attorney's Office,
or the FBI regarding the Investigation since mid-2003, neither the Company nor
its officers and directors can be certain that such requests will not be made in
the future. Furthermore, the ongoing Investigation has in the past occupied, and
may in the future occupy, a significant amount of time of the Company and
Messrs. Calvert and Provenzano personally, creating a distraction from the
Company's business. The mere existence of the Investigation, not to mention the
outcome thereof, depending upon such outcome, could have a material adverse
effect on the Company, its ability to obtain financings to execute its business
plan and its eventual results of operations.


ITEM 2. DESCRIPTION OF PROPERTY

      The Company's offices are located at 2603 Main Street, Suite 1155, Irvine,
California 92614. The Company currently occupies space from a consultant at no
cost to the Company.


ITEM 3. LEGAL PROCEEDINGS

      In June 2002, Geraldine Lyons, the Company's former Chief Financial
Officer, sued the Company and the Company's former president Todd Sanders, for
breach of her employment contract. The lawsuit was brought in the Circuit Court
of the 11th Judicial Circuit in Miami-Dade County in Florida. Ms. Lyons seeks
approximately $25,000 due under the contract and the issuance of 100,000 shares
of common stock, with a guarantee that the stock could be sold by Ms. Lyons for
$300,000. Ms. Lyons alleges that additional funds are due under her employment
contract; that the contract requires the Company guarantee that she can sell for
$300,000 the 100,000 shares of stock the Company is required to issue her; and,
that Mr. Sanders promised to purchase from her 100,000 shares of Company common
stock held by her at the price of $4.00 per share.

      The Company has counter-sued Ms. Lyons for breach of fiduciary duty,
fraud, violation of Section 12(a)(2) of the Securities Act of 1933, violation of
Section 517.301 of the Florida Statutes, negligent misrepresentation, conversion
and unjust enrichment resulting from the required restatement of the Company's
financial statements for the years ended December 31, 2000 and December 31,
1999. The restatements corrected the previous omission of certain material
expenses related primarily to compensation expense arising from warrants issued
and repriced stock options, as well as other errors.

      The case is ongoing at this time, although it has not been vigorously
prosecuted by Ms. Lyons or the Company, in the Company's case primarily because
the Company had lacked the resources to do so. The Company entered into an
agreement ("Legal Defense Agreement") in December 2004 such that Augustine Fund
would pay for the legal expenses associated with the Company's defense and
affirmative claims in this lawsuit (with the right to withdraw funding at any
time), and in exchange would share any net proceeds awarded to the Company
pursuant to a settlement or judgment. The sharing arrangement provides that
Augustine Fund will recover first, out of any money available from recovery, its
legal and out of pocket expenses related to the lawsuit; second, 85% of any
additional amounts recovered up to $500,000; and third, 50% of amounts recovered
beyond $500,000. While the Company believes that it has meritorious positions in
this litigation, given the inherent nature of litigation, it is not possible to
predict the outcome of this litigation or the impact it would have on the
Company.

      In May 2004, the Company was sued by Flight Options, Inc. ("Flight
Options"), a jet plane leasing company, in the Superior Court of Orange County
California. The lawsuit alleges that the Company owes Flight Options
approximately $418,300, pursuant to a five-year lease assigned to the Company by
the Company's former president Todd Sanders, from his corporation, Devenshire
Management Corporation ("Devenshire"). Management of the Company believes that
the assignment of the lease was not properly authorized or approved by the
Company, and that by Mr. Sander's failure to identify the lease in a December
2002 settlement agreement with the Company, he breached the terms of that
settlement agreement and, pursuant to the settlement agreement, must indemnify
the Company for any losses owed to Flight Options. The Company filed a
cross-complaint against Mr. Sanders and Devenshire seeking indemnity and
alleging Mr. Sander's breached his fiduciary duties in connection with the
assignment of the lease. The Company's Legal Defense Agreement with the
Augustine Fund applies also to the Flight Options litigation.

                                       12
<PAGE>

      On March 17, 2005, the Company settled with Flight Options pursuant to a
stipulation that would have allowed the Company to pay Flight Options $100,000
on or before August 5, 2005; if $100,000 was not paid by August 5, 2005, Flight
Options could file a judgment against the Company for $163,310. The Company did
not make a payment on or before August 5, 2005. Subsequently, the parties agreed
that the Company would pay Flight Options a total of $116,000, which amount was
paid. In exchange, Flight Options dismissed the case.

      At about the time of the settlement with Flight Options, the Company, Mr.
Sanders and Devenshire agreed to submit the matters in the cross-complaint,
including the indemnity claim, to binding arbitration. On March 7, 2006, an
arbitrator issued a binding award in favor of the Company and against Mr.
Sanders for $120,000.

      Legal Fees in the matter have been paid by Augustine, pursuant to the
Legal Defense Agreement between Augustine and the Company. In January 2006,
Augustine and the Company agreed to modify the terms of the Legal Defense
Agreement to allow for both parties to share in any amounts which might be
recovered from Sanders, on a percentage basis equal to the respective costs
incurred by each party. Legal Fees incurred by Augustine are estimated to be
approximately $81,000 as of February 2006, but will likely increase.

      On December 4, 2004, the Company was sued by the law firm of Enenstein
Russell and Saltz, LLP to collect fees that had been billed to the Company in
the amount of $15,233, which had been disputed by the Company. In August of
2005, the Company settled the lawsuit for $9,000. The Company paid the
settlement and the law firm dismissed the lawsuit.

      The Company is party to various other claims, legal actions and complaints
arising periodically in the ordinary course of business. In the opinion of
management, no such matters will have a material adverse effect on the Company's
financial position or results of operations.


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None.



                                       13
<PAGE>

                                     PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

MARKET INFORMATION

      From October 31, 1998 until June 10, 2003, the Company's common stock was
listed on the NASDAQ Small Cap Market. Since such date, the Company's common
stock has been quoted on the National Quotation Service Bureau, commonly known
as the "pink sheets", under the symbol "NMED".

      The table below represents the quarterly high and low bid prices for the
Company's Common Stock for the last two fiscal years as reported by Historical
Stock Price Reports available at www.yahoo.com.


                                            2004                 2005
                                    -------------------   ------------------
                                     HIGH        LOW       HIGH       LOW
                                    --------   --------   -------   --------
First Quarter                       $  0.01    $  0.01    $ 0.02    $  0.01
Second Quarter                      $  0.01    $  0.01    $ 0.02    $  0.01
Third Quarter                       $  0.01    $  0.01    $ 0.04    $  0.01
Fourth Quarter                      $  0.01    $  0.01    $ 0.02    $  0.01

      The closing price for the Company's common stock on December 29, 2005, the
last day on which the Company's stock traded in 2005, was $.01 per share. As of
December 30, 2005, there were approximately 280 registered owners and of the
Company's common stock. The Company believes that the number of beneficial
owners is substantially higher than this amount.

      At December 31, 2005, the Company also had the following warrants
outstanding:

           o        stock purchase warrants to purchase an aggregate 519,322
                    shares of the Company's common stock, which warrants had
                    been issued in private offerings. These warrants allow for
                    the holder to purchase shares of common stock at an exercise
                    price of $0.20 per share through March 7, 2006 (120,000
                    shares) and April 15, 2006 (399,322 shares).

           o        stock purchase warrants to purchase an aggregate 6,158,381
                    shares of the Company's common stock, which warrants had
                    been issued in a private offering to the Augustine Fund.
                    These warrants initially allowed for the holder to purchase
                    shares of common stock at an exercise price of $0.16 per
                    share through August 10, 2008, but were re-priced in 2004
                    (in conjunction with an extension of the financing provided
                    by Augustine Fund) to $0.035 per share.

           o        stock purchase warrants to purchase an aggregate 333,333
                    shares of the Company's common stock, which warrants had
                    been issued to a consultant that provided services to the
                    Company. These warrants allow for the holder to purchase
                    shares of common stock at an exercise price of $0.06 per
                    share through August 29, 2008.

           o        Stock purchase warrants to purchase an aggregate of
                    8,000,000 shares of the Company's common stock, which
                    warrants had been issued to the Augustine fund as
                    consideration for the extension of the maturity date of the
                    Augustine Loan. These warrants allow for the holder to
                    purchase shares of common stock at an exercise price of
                    $0.005 per share through July 29, 2010.

           o        Stock purchase warrants to purchase an aggregate of
                    11,980,000 shares of the Company's common stock, which
                    warrants had been issued in a private offering to twelve
                    investors. These warrants allow for the holder to purchase
                    shares of common stock at an exercise price of $0.05 per
                    share through January 31, 2008.

                                       14
<PAGE>

DIVIDENDS

      The Company has never declared or paid a cash dividend to stockholders.
The board of directors presently intends to retain any earnings which may be
generated in the future to finance Company operations.

SALES OF UNREGISTERED SECURITIES

      FIRST OFFERING

      In January 2005, pursuant to a private offering that commenced in October
2004 and terminated in January 2005 (the "First Offering"), the Company received
gross and net proceeds of $25,000 from an outside investor and issued its
convertible promissory note (the "First Offering Note") due and payable one year
from the date of issuance. The First Offering Note bears interest at a rate of
10% per annum, payable on the maturity date. The First Offering Note can be
converted, in whole or in part, into shares of the Company's Series A Preferred
stock, on the basis of $.005 per share, at any time prior to maturity by either
the Company or the lender. Each share of Series A Preferred Stock may be
converted by the holder into one share of the Company's common stock. If the
noteholder converts the First Offering Note into Series A Preferred Stock, on or
after the note's original maturity date the noteholder may require the Company
to buy back the shares of Series A Preferred Stock for 110% of the principal
amount of the note. If the Company is unable to do so, the Company's president,
Dennis Calvert, has agreed to buy back the shares on the same terms. If shares
of Series A Preferred Stock are converted into common stock, the holder has the
right to include (piggyback) the shares of common stock in a registration of
securities filed by the Company, other than on Form S-4 or Form S-8.

      The Company's payment obligations under the First Offering Note may be
accelerated upon the following events: (i) the sale of the Company's assets
outside the ordinary course of business; (ii) a breach of the representations
and warranties contained within the evidencing the loan; (iii) the failure to
timely pay the note; (iv) the Company's default in any other loan obligation
greater than $100,000; (v) the Company's dissolution, liquidation, merger,
consolidation, bankruptcy, or future insolvency; and (vi) the commencement of
any suit that threatens to have a material adverse effect on the Company,
including the entry of a final judgment or settlement in excess of $100,000.

      SECOND OFFERING

      In January 2005, pursuant to a private offering that commenced in that
month and terminated in August 2005 (the "Second Offering"), the Company
received gross and net proceeds of $75,000 from two outside investors and issued
its convertible promissory note (the "Second Offering Note") due and payable one
year from the date of issuance. The Second Offering Note bears interest at a
rate of 10% per annum, payable on the maturity date. The Second Offering Note
can be converted, in whole or in part, into shares of the Company's common
stock, on the basis ranging from $.005 to $0.016 per share, at any time prior to
maturity by either the Company or the holder. The holder has the right to
include (piggyback) the shares of common stock in a registration of securities
filed by the Company, other than on Form S-4 or Form S-8.

      The Company's payment obligations under the Second Offering Note may be
accelerated upon the following events: (i) the sale of the Company's assets
outside the ordinary course of business; (ii) a breach of the representations
and warranties contained within the evidencing the loan; (iii) the failure to
timely pay the note; (iv) the Company's default in any other loan obligation
greater than $100,000; (v) the Company's dissolution, liquidation, merger,
consolidation, bankruptcy, or future insolvency; and (vi) the commencement of
any suit that threatens to have a material adverse effect on the Company,
including the entry of a final judgment or settlement in excess of $100,000.

                                       15
<PAGE>

      In February 2005, the Company received gross proceeds of $51,000 and net
proceeds of $47,000 from four outside investors and issued Second Offering Notes
which allow conversion into an aggregate total of 5,558,036 shares of common
stock (at a conversion price of approximately $0.009 per common share).

      In April 2005, the Company received gross proceeds of $29,000 and net
proceeds of $23,750 from two outside investors and issued Second Offering Notes
which allow conversion into an aggregate total of 2,500,000 shares of common
stock (at a conversion price of approximately $0.009 per common share).

      In May 2005, the Company received gross and net proceeds of $50,000 and
$47,500 from an outside investor and issued a Second Offering Note which allows
conversion into a total of 7,142,857 shares of common stock (at a conversion
price of $0.007 per common share).

      In June 2005, the Company received gross and net proceeds of $256,120 from
eleven outside investors and issued Second Offering Notes which allow conversion
into an aggregate total of 28,612,000 shares of common stock (at a weighted
average conversion price of approximately $0.009 per common share).

      Also in July 2005, the Company received gross proceeds of $10,000 and net
proceeds of $9,500 from an outside investor and issued a Second Offering Note
which allows conversion into an aggregate total of 625,000 shares of common
stock (at a conversion price of $0.016 per common share).

      In August 2005, the Company received gross proceeds of $260,000 and net
proceeds of $252,000 from five outside investors and issued Second Offering
Notes which allow conversion into an aggregate total of 16,250,000 shares of
common stock (at a conversion price of $0.016 per common share).

      THIRD OFFERING

      Pursuant to another private offering that commenced in September 2005 and
terminated in February 2006, on December 31, 2005, the Company sold an aggregate
amount of $299,500 of its promissory notes (the "Third Offering Notes") due and
payable January 31, 2007 to twelve individual investors. Each Third Offering
Note bears interest at a rate of 10% per annum, and can be converted, in whole
or in part, into shares of the common stock of the Company at an initial
conversion price of $0.025 per share.

      The Third Offering Notes may not be converted by either the Company or the
holder unless and until each of the following events has first occurred: (i) the
Company's stockholders have approved an increase in the number of shares of
common stock authorized by the Company's Certificate of Incorporation in an
amount not less than the amount required to permit all notes and warrants issued
in this series to be converted into shares of the Company's Common Stock as
provided herein, at a validly held meeting of stockholders at which a quorum is
present and acting throughout; and (ii) the Company has filed with the Secretary
of State of State of Delaware a Certificate of Amendment to the Company's
Certificate of Incorporation to amend its Certificate of Incorporation to
increase the number of shares of common stock authorized by the Company's
Certificate of Incorporation.

      Purchasers of the Third Offering Notes received, for no additional
consideration, a stock purchase warrant (the "Third Offering Warrant") entitling
the holder to purchase a number of Shares of Common Stock equal to the number of
Shares of Common Stock into which the Third Offering Note is convertible. The
Third Offering Warrant is exercisable at an initial price of $0.05 per Share and
will expire on January 31, 2008.

                                       16
<PAGE>

      OTHER ISSUANCES

      In July 2005, the board of directors of the Company approved the issuance
of 6,000,000 shares of the Company's common stock to two directors and one
officer. An aggregate $20,000 owed by the Company to two independent directors
for unpaid compensation for serving on the board of directors was paid by the
issuance of an aggregate 2,000,000 shares of the Company's common stock, at a
share price of $0.01 per share; and $40,000 owed by the Company to an officer of
the Company for accrued and unpaid compensation, was paid by the issuance of an
aggregate 4,000,000 shares of the Company's common stock, at a share price of
$0.01 per share.

      Also in July 2005, the Company's board of directors approved the issuance
of an aggregate of 4,390,000 shares of the Company's common stock to two
consultants, at a share price of $0.01 per share. This issuance was in
satisfaction of an aggregate of $43,900 owed by the Company for services
previously performed by these individuals.

      All of these offerings and sales were made in reliance on the exemption
from registration contained in Section 4(2) of the Securities Exchange Act
and/or Regulation D promulgated thereunder as not involving a public offering of
securities.

      Until the Company's stockholders approve an amendment to the Company's
charter to increase the number of authorized shares of common stock, the Company
will be unable to fulfill its obligations to all convertible noteholders to
permit the conversion into common stock of amounts due pursuant to the terms of
the convertible notes. In the event that the Company has not raised further
capital prior to the maturity dates of the convertible notes, the Company would
be in default of those notes if its stockholders have not formally approved an
increase in the number of authorized common shares. The Company is not, at this
time, in default of the convertible notes.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS


                      EQUITY COMPENSATION PLAN INFORMATION

<TABLE>
<CAPTION>
                                                      Number of      Weighted average
                                                  securities to be    exercise price
                                                     issued upon      of outstanding
                                                     exercise of         options,           Number of
                                                     outstanding       warrants and        securities
                                                      options,            rights            remaining
                                                    warrants and                          available for
                 Plan category                         rights                           future issuance
-----------------------------------------------------------------------------------------------------------
                                                         (a)                (b)                (c)
-----------------------------------------------------------------------------------------------------------
<S>                                                               <C>                <C>                <C>
Equity compensation plans approved by security                    0                  0                  0
holders
Equity compensation plans not approved by
security holders                                                  0                  0         14,320,000
-----------------------------------------------------------------------------------------------------------
Total                                                             0                  0         14,320,000
                                                   ================   ================   ================
</TABLE>

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

      The following discussion and analysis should be read in conjunction with
our audited consolidated financial statements and the related notes to the
consolidated financial statements included elsewhere in this report.

      This discussion contains forward-looking statements that involve risks and
uncertainties. Such statements, which include statements concerning future
revenue sources and concentration, selling, general and administrative expenses,
research and development expenses, capital resources, additional financings and
additional losses, are subject to risks and uncertainties, including, but not
limited to, those discussed above in Part I, Item 1 and elsewhere in this Form
10-KSB, particularly in "Risk Factors," that could cause actual results to
differ materially from those projected. The forward-looking statements set forth
in this Form 10-KSB are as of December 31, 2005, and we undertake no duty to
update this information.

                                       17
<PAGE>

PLAN OF OPERATIONS

      The Company had no continuing business operations as of December 31, 2005.
At this time, the Company is operating as a public shell and management is
seeking merger and acquisition candidates with ongoing operations. The Company
has identified an acquisition candidate, BioLargo, the owner of the BioLargo
technology. The Company and BioLargo have entered into the M & L Agreement and
the Company intends to acquire substantially all of the assets of IOWC, subject
to various conditions, including approval of the Company's stockholders.

      Over the course of several years, the Company had attempted to enter
various businesses through the acquisitions of entities operating ongoing
businesses or technology that needed to be developed and marketed. However, as a
result of various factors, primarily inadequate capital and the inability to
raise sufficient financing successfully, these acquisitions could not be
properly exploited and integrated to produce profitable operations by the
Company and such acquisitions were disposed of or abandoned.

      The Company is presently focused primarily on maintaining the corporate
entity and seeking new business opportunities. The Company will need working
capital resources to maintain the Company's status and to fund other anticipated
costs and expenses during the year ending December 31, 2006 and beyond. The
Company's ability to continue as a going concern is dependent on the Company's
ability to raise capital to, at a minimum, meet its corporate maintenance
requirements. If the Company is able to acquire an ongoing business and/or
technology that must be exploited, it would need additional capital until and
unless that prospective operation is able to generate positive working capital
sufficient to fund the Company's cash flow requirements form operations.

      As a result of the dramatic change in direction of the Company's scope and
focus, and the discontinuation of its previous operating businesses in 2004,
comparisons of year-to-year results of operations are not meaningful.

RESULTS OF OPERATIONS - COMPARISON OF THE YEARS ENDED DECEMBER 31, 2005 AND 2004

      REVENUE

      The Company had no revenues from operations during either 2005 or 2004.

      SELLING, GENERAL AND ADMINISTRATIVE EXPENSE

      Selling, and General and Administrative expenses were $945,000 for the
year ending December 31, 2005, as compared to $970,000 for the year ending
December 31, 2004, or a net decrease of 3%. The largest components of these
expenses were:

                  a. Salaries and Payroll-related Expenses: These expenses were
         $220,000 in 2005, compared to $371,000 in 2004, a decrease of $151,000
         or 41% percent. The decrease is primarily attributable to an expense
         recorded by the company in the prior year for the issuance of 3,000,000
         shares of the Company's common stock to an officer of the Company in
         lieu of cash compensation in the amount of $118,000.

                  b. Consulting Expenses: These expenses were $324,000 in 2005,
         compared $24,000 in 2004, an increase of $300,000. The increase is
         primarily attributable to the increase in the Company's need for
         outside consultants, including Mr. Code, the inventor of the BioLargo
         technology, to assist the Company in preparing a comprehensive business
         plan for the commercialization of the BioLargo technology; with
         advising the Company in various respects regarding the BioLargo
         business and opportunities; further product development and design;
         financial, valuation and marketing services; licensing, initial
         marketing and pre-sale research and activities; and various other
         consulting services. The increase is also partially attributable to a
         reversal of accrued consulting expense relating to the issuance (and
         subsequent return to treasury) of the Company's common stock in 2004.

                                       18
<PAGE>

                  c. Legal Expenses: These expenses were $199,000 in 2005,
         compared to $307,000 in 2004, a decrease of $108,000. This decrease is
         primarily attributable to the high level of legal services required
         during 2004 with respect to the Premium Medical Group, Inc ("PMG")
         acquisition and operations, which acquisition was later rescinded,
         partially offset by increased legal work associated with the Company's
         financing efforts and the IOWC Transactions.

                  d. Independent Director Compensation: These expenses were
         $120,000 in both 2005 and 2004.

                  e. Settlement Charge: This expense was $0 in 2005, compared to
         $163,000 in 2004, a decrease of $163,000. This decrease is attributable
         to the settlement reached in the Flight Options litigation in 2004, in
         which the Company may be obligated to pay up to approximately $163,000
         to Flight Options (See Part I, Item 3, "Legal Proceedings").

                  f. Reversal of Accrued Liability. In 2005, management reviewed
         the Company's accrued liabilities and reversed an accrual for rental
         expense of $55,000, which it currently believes that the Company will
         no longer have to pay.

      EXPENSES ASSOCIATED WITH STOCK ISSUED FOR SERVICES

      In 2005, the Company recorded an expense of $13,900 related to the
issuance of 1,390,000 shares to one consultant. An additional amount of $90,000
related to the issuance of 9,000,000 shares was recorded to reduce liabilities
in connection with prior services by advisory board members, lawyers and
directors.

      In 2004, the Company recorded an expense of $333,000 related to the
issuance of 9,900,000 shares to approximately 14 directors, employees and
consultants. Of this amount, $135,000 related to consulting services, $80,000
related to service by directors and advisory board members, and $118,000 related
to salary expense.

      NET LOSS

      Net Loss for the year ended December 31, 2005 was $1,187,301 or $0.01 per
share, compared to a net loss for the year ended December 31, 2004 of
$1,218,048, or $.03 per share.

LIQUIDITY AND CAPITAL RESOURCES

      Cash and cash equivalents totaled $283,462 at December 31, 2005. The
Company had no revenues in the twelve-month period ended December 31, 2005 and
was forced to consume cash on hand to fund operations. The Company's cash
position is insufficient to meet its expenses or its obligations under the LOI
with IOWC to acquire the BioLargo Technology. The Company will be required to
raise additional capital to sustain basic operations through the remainder of
2006 and to consummate the transactions with IOWC. While the Company is actively
seeking investments through private investors and other parties, there is no
assurance that the Company will be able to raise additional capital for the
entire period required.

                                       19
<PAGE>

      The Company has approximately $2,740,570 aggregate principal amount of its
promissory notes that mature at various times during 2006. The Company does not
presently have funds sufficient to repay these obligations as they mature. Even
though the terms of all of these notes permit the noteholder to convert the
notes into shares of our common stock, until the Company's stockholders approve
an amendment to the Company's charter to increase the number of authorized
shares of common stock, the Company will be unable to fulfill its obligations to
all noteholders to permit the conversion into common stock of amounts due
pursuant to the terms of the notes. In the event that the Company has not raised
further capital prior to the maturity dates of the convertible notes, the
Company would be in default of those notes if its stockholders have not formally
approved an increase in the number of authorized common shares, or unless the
Company is able to refinance or renegotiate the terms of these notes. No
financing is in place at present, and it is unknown if any financing will be in
place in the future, which would permit the Company to repay these notes in full
as they mature.

      The financial statements accompanying this Annual Report have been
prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of our
business. As reflected in the accompanying financial statements, the Company had
a net loss of $1,187,301 for the twelve-month period ended December 31, 2005,
negative cash flow from operating activities of $825,008 for the twelve-month
period ended December 31, 2005, and a stockholders' deficiency of $28,229,187 as
of December 31, 2005. Also, as of December 31, 2005, the Company had limited
liquid and capital resources. The foregoing factors raise substantial doubt
about the Company's ability to continue as a going concern. Ultimately, the
Company's ability to continue as a going concern is dependent upon its ability
to attract new sources of capital, establish an acquisition or reverse merger
candidate with continuing operations, such as IOWC, attain a reasonable
threshold of operating efficiencies and achieve profitable operations. The
financial statements do not include any adjustments that might be necessary if
the Company is unable to continue as a going concern.

      During 2005, the Company raised $1,055,620 gross proceeds ($1,035,370 net
proceeds) in three private offerings. This amount consisted of (i) $25,000 gross
proceeds which was raised in the First Offering; (ii) $756,120 gross proceeds
($735,870 net proceeds) which was raised in the Second Offering; and (iii)
$299,500 gross and net proceeds which was raised in the Third Offering. See Part
II, Item 5 "Sales of Unregistered Securities".

      In the First Offering, the Company offered the First Offering Notes, which
are due and payable one year from the date of issuance. The First Offering Notes
bear interest at a rate of 10% per annum, payable on the maturity date, and can
be converted, in whole or in part, into shares of the Company's preferred stock,
on a basis of $.005 per share, at any time prior to maturity by either the
Company or the holder. See Part II, Item 5 "Sales of Unregistered Securities".

      In the Second Offering, the Company offered the Second Offering Notes due
and payable one year from the date of issuance. The Second Offering Notes bear
interest at a rate of 10% per annum, payable on the maturity date, and can be
converted, in whole or in part, into shares of the Company's common stock, on a
basis of ranging from $.005 to $0.016 per share, at any time prior to maturity
by either the Company or the holder. See Part II, Item 5 "Sales of Unregistered
Securities".

      In the Third Offering, the Company offered up to $1 million of the Third
Offering Notes due and payable on January 31, 2007. The Third Offering Notes
bear interest at a rate of 10% per annum, payable on the maturity date, and can
be converted, in whole or in part, into shares of the Company's common stock, on
a basis of $0.025 per common share, at any time prior to maturity by either the
Company or the holder. Purchasers of the Notes will receive, for no additional
consideration, a stock purchase warrant (the "Third Offering Warrant") entitling
the holder to purchase a number of Shares of Common Stock equal to the number of
Shares of Common Stock into which the Note is convertible, at an initial price
of $0.05 per Share, with an expiration of October 31, 2007. The Company amended
the terms of the Third Offering to increase the amount of the offering to up to
$2 million, extend the expiration of the offering, extend the maturity date of
the Third Offering Notes to January 31, 2007, and extend the expiration of the
Third Offering Warrants to January 31, 2008. The Third Offering terminated on
February 21, 2006, by which date the Company had raised $1,102,000 gross and net
proceeds. Of this amount, $299,500 was raised during 2005. See Part II, Item 5
"Sales of Unregistered Securities".

                                       20
<PAGE>

      Even with the successful completion of the Third Offering, the Company
will be required to raise additional capital to sustain its operations and meet
its liabilities as they become due for the next twelve months, as well as to
consummate the transactions with IOWC, fund the operations of the Company after
the transactions are consummated and meet its obligations, including the First
Offering Notes, the Second Offering Notes, and the Third Offering Notes, as they
mature.

      SIGNIFICANT DEBT OBLIGATIONS

      Significant debt obligations at December 31, 2005 included:

      (i) $420,000 due to the Augustine Fund, together with accrued but unpaid
      interest, described in more detail below;

      (ii) a $1,120,000 note payable which was purchased in March 2003 by New
      Millennium, an entity owned and controlled by the Company's president,
      Dennis Calvert, and certain members of his family, together with accrued
      but unpaid interest, described in more detail below;

      (iii) amounts owed to Mr. Calvert personally in the aggregate amount of
      approximately $337,796, as described below;

      (iv) convertible promissory notes to various investors pursuant to the
      First Offering, the Second Offering, and the Third Offering, in the
      aggregate principal amount of $1,165,570, plus accrued interest;

      (v) approximately $21,000 outstanding remaining on a settlement agreement
      with former convertible debenture holders; and

      (vi) $35,000 in remaining balance due to a former advisory board member,
      from a promissory note dated November 20, 2003 in the original principal
      amount of $65,000.

      For the twelve-month period ended December 31, 2005, there was $579,000 of
accrued interest recorded related to these obligations.

      The Company has received extensions on the repayment of $230,000 principal
amount of the First Offering Notes and Second Offering issued between October
2004 through May 2005, with various maturity dates through May 2, 2006, together
with accrued and unpaid interest thereon. Assuming that at the 2006 Annual
Meeting the Company's, stockholders approve the BioLargo transactions and a
proposal to increase the number of authorized shares of the Company's common
stock, the Company intends to exercise its right to convert the First Offering
Notes, the Second Offering Notes, and the Third Offering Notes, along with
accrued and unpaid interest thereon, into shares of the Company's common stock.


      AUGUSTINE FUND NOTE

      On June 10, 2003 the Company entered into a Term Loan Agreement ("Loan
Agreement") with the Augustine Fund, pursuant to which the Augustine Fund agreed
to lend the Company $420,000, payable in installments of $250,000, $100,000, and
$70,000 (the "Augustine Loan"). The proceeds of the Augustine Loan were used by
the Company for working capital.

      Principal and interest, at an annual rate of 10%, of the Augustine Loan,
was originally due on February 29, 2004. In addition, the Loan Agreement
contains certain requirements that the Company make mandatory prepayments of the
Augustine Loan from the proceeds of any asset sales outside of the ordinary
course of business, and, on a quarterly basis, from positive cash flow. In
addition, all or any portion of the Augustine Loan may be prepaid by the Company
may prepay all or any portion of the Augustine Loan at any time without premium
or penalty.

                                       21
<PAGE>

      As additional consideration for making the Augustine Loan, the Augustine
Fund received five-year warrants to purchase up to 6,158,381 shares of the
Company's common stock at an exercise price of $0.16 per share. The Company
could require that the warrants be exercised if certain conditions were
satisfied. Since these conditions were not fully satisfied by the maturity date,
the Loan Agreement provides that the Augustine Fund may, at any time following
the maturity date and so long as the warrants remain exercisable, elect to
exercise all or any portion of the warrants pursuant to a "cashless exercise",
whereby the Augustine Fund would be issued the net amount of shares of our
common stock, taking into consideration the difference between the exercise
price of the warrants and the fair market value of our common stock at the time
of exercise, without having to pay anything to the Company for such exercise.

      As security for the Augustine Loan, New Millennium, pledged 2.5 million
shares of the Company's common stock owned by New Millennium, and, in addition,
the Company has granted the Augustine Fund a security interest in its 51%
membership ownership interest in NuWay Sports. As a result, the Company will
need to consent of the Augustine Fund to release its security interest in NuWay
Sports if the Company is able to sell NuWay Sports.

      Prior to the original maturity date of the Augustine Loan, the Company
spoke with representatives of the Augustine Fund and advised them that the
Company was unable to pay the amount due under the Augustine Loan by the
February 29, 2004 maturity date. On March 30, 2004, the Augustine Fund agreed to
extend the maturity date of the Loan Agreement to August 2004. In addition to
the extension of the maturity date, the Augustine Fund was given the option of
having the Augustine Loan satisfied in cash or by the conversion of any
remaining principal balance and any accrued interest on the Augustine Loan to
shares of the Company's common stock at a 15% discount to market, so long as
Augustine Fund's holdings do not exceed 4.9% of the total issued and outstanding
shares of the Company's common stock at any time. In addition, the warrants held
by the Augustine Fund to purchase 6,158,381 shares of the Company's common stock
were re-priced to an exercise price of $.035 per share. Exercise of the warrants
is also subject to the limit that the Augustine Fund does not hold more than
4.9% of the issued and outstanding shares of the Company's common stock. The
Company recorded $19,000 and $50,000 of interest expense for the three- and
nine-month periods ended September 30, 2004, related to the Augustine Loan.

On March 7, 2005, the Company and the Augustine Fund agreed to extend the
maturity date of the Augustine Loan to May 2006, in exchange for the issuance of
a warrant that gives the Augustine Fund the right to purchase 8,000,000 shares
of the Company's common stock at $0.005 per share for a period of five years. On
July 29, 2005, the Company and the Augustine Fund finalized the terms of this
amendment to the Augustine Loan and executed formal documentation, in which the
parties agreed to further extend the maturity date to May 2006. In exchange, the
Company issued a warrant that gives the Augustine Fund the right to purchase
8,000,000 shares of the Company's common stock at $0.005 per share for a period
of five years. Accordingly, as of December 31, 2005, the principal amount of the
loan, together with approximately $546,780 in accrued but unpaid interest, had
not been repaid.

      OBLIGATION TO NEW MILLENNIUM

      In conjunction with the acquisition from Med Wireless of the license for
the Med Wireless and PRLS technologies on August 21, 2002, the Company assumed a
$1,120,000 note (the "Med Wireless Note") with interest at 10% per annum payable
by Med Wireless to Summitt Ventures, Inc. ("Summitt Ventures"). Summitt Ventures
is controlled by Mark Anderson, a former consultant and principal stockholder of
the Company. The Med Wireless Note is secured by the Company's assets and was
originally due on June 15, 2003.

      As part of a series of transactions that the Company undertook to separate
itself completely from Mr. Anderson, on March 26, 2003, Summitt Ventures sold
the Med Wireless Note, together with 4,182,107 shares of the Company's common
stock owned by Mr. Anderson's affiliates, Camden Holdings and Summit Healthcare,
to New Millennium, in exchange for a $900,000 promissory note issued by New
Millennium in favor of Summitt Ventures, Camden Holdings, and Summit Healthcare
(the New Millennium Note; see Part I, Item 1, "Business-Overview"). The New
Millennium Note is secured by all of the stock of the Company owned by New
Millennium and Mr. Calvert. (See "Augustine Fund Note" above.) Other than Mr.
Calvert, no individual, entity or party presently or previously associated with
the Company has ever had any ownership interest in New Millennium. Mr. Anderson,
a principal of those companies that sold and/or licensed the technologies to the
Company, conditioned the transaction with New Millennium on the Company's
agreeing to convert the Med Wireless Note to common stock.

                                       22
<PAGE>

      Since New Millennium purchased the Med Wireless Note, the Company has
attempted multiple times to convert the Med Wireless Note, but has been unable
to obtain the required stockholder vote, due to a lack of quorum, to do so. The
three attempts are described below.

      On March 26, 2003, the Company's board of directors voted to convert the
Med Wireless Note by New Millennium into 22,400,000 shares of common stock of
the Company, at a conversion price discounted 37.5% from the then market price
of $0.08. New Millennium agreed to this conversion.

      In arriving at a conversion price, the board of directors determined that
a 37.5% discount to market price was appropriate based on a number of factors,
including that (i) with the quantity of the shares that would be issued, a block
of shares that size could not be liquidated without affecting the market price
of the shares, and (ii) the shares would be "restricted shares" and could
therefore not be sold by New Millennium in the public markets prior to two years
from the date of the conversion, and thereafter would be subject to the volume
and manner of sale limitations of Rule 144 under the Securities Act of 1933.

      Subsequent to the vote by the board to convert the Med Wireless Note, the
Company received notification from NASDAQ's Listing Qualifications Department
that converting the Note without stockholder approval violated certain NASDAQ
Marketplace Rules. In response to this notification, the board, with the
concurrence of New Millennium, voted to amend its resolution and delay
conversion of the Note until the Company's stockholders approved the conversion.

      At the Company's June 6, 2003 board meeting, Mr. Calvert, on behalf of New
Millennium, and the Company, through the unanimous action of the board (with Mr.
Calvert abstaining), agreed that, in light of current market conditions (namely
the significant increase in the trading price of the Company's common stock
since March 26, 2003, the date on which the conversion of the Note was
originally approved by the board, from $0.08 to $0.28 as of June 6, 2003), it
would be inequitable for New Millennium to convert the Med Wireless Note at the
originally agreed to $0.05 per share price. Mr. Calvert, on behalf of New
Millennium, and the Company orally agreed to rescind the agreement to convert
the Med Wireless Note.

      In addition, New Millennium orally agreed with the Company to extend the
maturity date of the Med Wireless Note to a first payment due October 1, 2003 in
the amount of $100,000 and the balance of the principal due on April 1, 2004,
with interest due according to the original terms of the Med Wireless Note (to
correspond to the payment terms of the New Millennium Note), and furthermore to
reduce the Company's obligation on the Note to the extent that New Millennium
might be able to reduce its obligation on the New Millennium Note. While the
prior holder of the Med Wireless Note, Summitt Ventures, purported to condition
New Millennium's purchase on the conversion of the Med Wireless Note, Mr.
Calvert has represented to the Company that due to Mr. Anderson's failure to
honor his obligations in the purchase agreement, Mr. Calvert now believes that
conversion of the Med Wireless Note is no longer a required term of the
agreement between New Millennium and Summitt Ventures.

      The Company was unable to make the $100,000 payment on the Med Wireless
Note on the extended due date of October 1, 2003. At a board meeting on October
15, 2003, the board decided to put the issue of conversion of the Med Wireless
Note to the Company's stockholders at a special meeting of the stockholders
scheduled for December 9, 2003. The stockholders meeting was held on December 9,
2003, but adjourned without a vote, because not enough shares to constitute a
quorum were represented. The stockholders meeting was rescheduled for December
30, 2003, at which a quorum was also not present. Because this was the second
attempt to obtain a quorum, and more than 4,000,000 additional shares were
required to be voted to obtain a quorum, the board adjourned the meeting
indefinitely. As a result, the Med Wireless Note was not converted into stock
and the outstanding principal amount, together with accrued and unpaid interest,
remains as a liability of the Company.

                                       23
<PAGE>

      In conjunction with the Company's January 31, 2004 purchase of PMG (later
rescinded in October 2004), and as a condition to that transaction (the "PMG
Transaction"), the Premium Medical Group shareholders (the "PMG Shareholders")
required the Company to convert the Med Wireless Note so as to eliminate the
obligation from the Company's balance sheet. At a meeting on February 10, 2004,
the board of directors voted to convert the Med Wireless Note into 30,869,992
shares of its common stock, at a conversion price of $0.04, discounted 20% from
the then market price of $0.05. New Millennium agreed to this conversion. In
arriving at a conversion price, the board of directors determined that a 20%
discount to market price was appropriate based on a number of factors, including
(i) the holding period of the stock will be two years, and thus is not liquid
until that point, and (ii) the amount of the stock issued would make it
impossible to liquidate the stock at the current market price. This discount was
equal to the discount proposed to the stockholders in December 2003 at the
abandoned stockholders meeting, and less than the discount used by the board at
the first conversion attempt in April 2003.

      The board approved the conversion knowing that, since its conversion was a
condition imposed by the PMG Shareholders, they (who would hold 45% of the
Company's common stock at the time of such meeting) would provide the additional
shares necessary to obtain a quorum and formal stockholder approval. Stockholder
approval was also necessary to increase the number of authorized shares
necessary to convert the Med Wireless Note. However, due to lack of operational
capital, the Company was unable to remain current in its SEC filings, and thus
was unable to hold the required stockholder meeting.

      In October 2004, the Company, PMG and the PMG Shareholders rescinded the
PMG Transaction. Because the board of director's decision to convert the Med
Wireless Note was based in part on the requirements of the PMG Shareholders, the
board on October 28, 2004, determined not to convert the Med Wireless Note.
Considering that the Company at the time was a shell corporation with no
operations, Mr. Calvert also agreed to extend the maturity of the Med Wireless
Note indefinitely until the Company's status changed.

      Accordingly, as of December 31, 2005, the principal amount of the Med
Wireless Note, together with $317,956 in accrued but unpaid interest, had not
been repaid.

      Under the terms of the New Millennium Note, it is possible that Summitt
Ventures, Camden Holdings and Summit Healthcare may have a claim to reacquire
the shares of the Company's common stock that were sold to New Millennium. The
New Millennium Note is purportedly secured by the purchased shares of the
Company's common stock; however, New Millennium and Mr. Calvert believe that Mr.
Anderson and his affiliates have not perfected their security interest in those
shares. In addition, the Augustine Fund is the pledgee of 2,500,000 of these
shares and has physical possession of those shares.

      Additionally, Mr. Calvert, the Company's President and CEO has proposed to
the Board of Directors a plan to amend the New Millennium Note to extend the due
date to January 15, 2008; waive any cash payments of interest until the New
Millennium Note becomes due; reduce the principal amount of the New Millennium
Note from $1,120,000 to $900,000, equal to a 19.6% reduction and New
Millennium's basis; and comparably reduce the accrued but unpaid interest due
under the terms of the New Millennium Note from $317,956 to $255,636, also equal
to a 19.6% reduction. The proposal is currently under consideration by the Board
of Directors but it is expected to approve the proposal.

      OBLIGATIONS TO DENNIS CALVERT

      In 2003 and 2004, the Company's President, Dennis Calvert, loaned money to
the Company by paying from his personal funds certain of the Company's expenses.
A significant portion of these personal funds was obtained by Mr. Calvert by
refinancing his primary residence and cashing out equity thereon. On March 7,
2005, the Company and Mr. Calvert agreed that the $101,770 still outstanding and
owed by the Company to Mr. Calvert would be repaid under the terms of a
promissory note bearing interest of 10% per annum, requiring monthly payments
and maturing on January 15, 2006. As of December 31, 2005, the Company had
repaid approximately $92,800 of this loan; approximately $9,000 principle
remained outstanding. Subsequent to the end of the fiscal year ended December
31, 2005, the balance of this obligation was repaid by the Company.

                                       24
<PAGE>

      As of December 31, 2005, the Company had accrued an expense related to the
unpaid accrued compensation due Mr. Calvert in the amount of $328,821.

      OBLIGATION TO DR. SEAY

      In February 2005, the Company amended its obligations to Dr. James Seay
under its promissory note dated November 20, 2003 in the principal amount of
$50,000 and which matured on February 18, 2004. On the maturity date of the note
the Company was obligated to pay Dr. Seay $65,000. The Company has paid Dr. Seay
$30,000 and the balance of $35,000 remains outstanding. The amendment to the
note entered into on February 10, 2005, (i) extends the maturity date of the
note to February 3, 2006, (ii) provides for interest to accrue at a rate of 10%
per annum (15% upon default), and (iii) allows for the conversion of the note
into 7,000,000 shares of the Company's common stock, or $.005 per share. In
February 2006, this note has been further extended to the sooner of June 30,
2006, or the date the Company's stockholders approve an amended to the Company's
charter increasing the number of authorized shares of common stock.


CRITICAL ACCOUNTING POLICIES

      The SEC recently issued Financial Reporting release No. 60, "Cautionary
Advice Regarding Disclosure About Critical Accounting Policies" (FRR 60"),
suggesting companies provide additional disclosure and commentary on their most
critical accounting policies. In FRR 60, the SEC defined the most critical
accounting policies as the ones that are most important to the portrayal of a
company's financial condition and operating results, and require management to
make its most difficult and subjective judgments, often as a result of the need
to make estimates of matters that are inherently uncertain. Based on this
definition, the Company's most critical accounting policies include: non-cash
transactions and compensation valuations that affect the total expenses reported
in the current period and/or values of assets received in exchange.

      The Company has established a policy relative to the methodology to
determine the value assigned to each intangible acquired with or licensed by the
Company and/or services or products received for non-cash consideration of the
Company's common stock. The value is based on the market price of the Company's
common stock issued as consideration, at the date of the agreement of each
transaction or when the service is rendered or product is received, as adjusted
for applicable discounts.

      The methods, estimates and judgments the Company uses in applying these
most critical accounting policies have a significant impact on the results of
the Company reports in its financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS

      In November 2004, the FASB issued SFAS No. 153, "Exchanges of Non-monetary
Assets - An Amendment of APB No. 29." The provisions of this statement are
effective for non-monetary asset exchanges occurring in fiscal periods beginning
after June 15, 2005. This statement eliminates the exception to fair value for
exchanges of similar productive assets and replaces it with a general exception
for exchange transactions that do not have commercial substance - that is,
transactions that are not expected to result in significant changes in the cash
flows of the reporting entity. The Company does not believe that the adoption of
SFAS 153 will have a significant effect on its future consolidated financial
statements.

                                       25
<PAGE>

      In May 2005, the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 154, "Accounting Changes and Error Corrections, a Replacement of
Accounting Principles Board (APB) Opinion No. 20 and FASB Statement No. 3." SFAS
154 requires retrospective application to prior periods' financial statements
for changes in accounting principles, unless it is impracticable to determine
either the period-specific effects or the cumulative effect of the change. SFAS
154 also requires that retrospective application of a change in accounting
principle be limited to the direct effects of the change. Indirect effects of a
change in accounting principle, such as a change in non-discretionary
profit-sharing payments resulting from an accounting change, should be
recognized in the period of the accounting change. SFAS 154 also requires that a
change in depreciation, amortization, or depletion method for long-lived,
non-financial assets be accounted for as a change in accounting estimate
effected by a change in accounting principle. SFAS 154 is effective for
accounting changes and corrections of errors made in fiscal years beginning
after December 15, 2005. Early adoption is permitted for accounting changes and
corrections of errors made in fiscal years beginning after the date this
Statement is issued. The Company is required to adopt the provisions of SFAS
154, as applicable, beginning in fiscal 2007. The Company does not believe the
adoption of SFAS 154 will have a significant effect on its future consolidated
financial statements.

      Other recent accounting pronouncements issued by FASB (including its
Emerging Issued Task Force), the American Institute of Certified Public
Accountants and the Securities and Exchange Commission did not or are not
believed by management to have a material impact on the Company's present or
future consolidated financial statements.


ITEM 7. FINANCIAL STATEMENTS.

      Our consolidated financial statements as of and for the years ended
December 31, 2005 and 2004 are presented in a separate section of this report
following Item 14 and begin with the index on page F-1.


ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.

      As disclosed in our Current Report on Form 8-K filed on September 10,
2004, as amended on September 17, 2004, we dismissed Haskell & White LLP ("H&W")
as our principal accounting firm as of September 9, 2004. As disclosed in our
Current Report on Form 8-K filed on September 16, 2004, we engaged Jeffrey S.
Gilbert, CPA ("Gilbert") as our principal accountant. Gilbert was engaged to
audit our consolidated financial statements for the year ended December 31,
2003. The decision to change auditors was recommended by our audit committee and
approved by our board of directors. During the Company's relationship with H&W,
since H&W's initial engagement as the principal auditors on March 31, 2003,
through September 9, 2004, there were no disagreements with H&W, whether or not
resolved, on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which, if not resolved to
H&W's satisfaction, would have caused it to make reference to the subject matter
of the disagreement(s) in connection with its report on the consolidated
financial statements for the year ended December 31, 2002.


ITEM 8A. CONTROLS AND PROCEDURES.

      (a) Evaluation of disclosure controls and procedures. Our management
evaluated, with the participation of Dennis Calvert, who serves as both our
Chief Executive Officer and Chief Financial Officer, the effectiveness of our
disclosure controls and procedures as of the end of the period covered by this
Annual Report on Form 10-KSB. Based on this evaluation, our Chief Executive
Officer and Chief Financial Officer have concluded that our disclosure controls
and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934) are effective to ensure that information required to be
disclosed by us in reports that we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified
in SEC rules and forms. It should be noted that the design of any system of
controls is based in part upon certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions, regardless of
how remote.

                                       26
<PAGE>

      (b) Changes in internal control over financial reporting. There was no
change in our internal control over financial reporting that occurred during the
period covered by this Annual Report on Form 10-KSB that has materially
affected, or is reasonably likely to materially affect, our internal control
over financial reporting.


IITEM 8B. OTHER INFORMATION.

      None



                                       27
<PAGE>

                                    PART III

      Certain information required by Part III is incorporated by reference from
our Proxy Statement to be filed with the SEC in connection with the solicitation
of proxies for our 2006 Annual Meeting of Stockholders to be held on April 18,
2006 (the "Proxy Statement").

ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS OF REGISTRANT

      The information required by this section is incorporated by reference from
the section entitled "Proposal 1 -- Election of Directors" in the Proxy
Statement. Item 405 of Regulation S-B calls for disclosure of any known late
filing or failure by an insider to file a report required by Section 16 of the
Exchange Act. This disclosure is incorporated by reference to the section
entitled "Section 16(a) Beneficial Ownership Reporting Compliance" in the Proxy
Statement. The information required by this Item with respect to our executive
officers is contained in Item 1 of Part I of this Annual Report under the
heading "Business -- Executive Officers".

ITEM 10. EXECUTIVE COMPENSATION

      The information required by this section is incorporated by reference from
the information in the section entitled "Executive Compensation" in the Proxy
Statement.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS

      The information required by this section is incorporated by reference from
the information in the section entitled "Security Ownership of Certain
Beneficial Owners and Management" in the Proxy Statement.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

      The information required by this section is incorporated by reference from
the information in the section entitled "Certain Relationships and Related
Transactions" in the Proxy Statement.

ITEM 13. EXHIBITS

      (a) The following documents are filed as part of this Form 10-KSB.

      Financial Statements:

      Reference is made to the contents to Financial Statements of Nuway
      Medical, Inc. under Item 7 of this Form 10-KSB.

      (b) Exhibits:

      The exhibits listed below are required by Item 601 of Regulation S-B.

Exhibit No.       Description of Exhibit
----------        ----------------------

3.1               Certificate of Incorporation (1)

3.2               Certificate of Amendment of Certificate of Incorporation filed
                  11/26/1991 (9)

3.3               Certificate of Amendment of Certificate of Incorporation filed
                  6/24/1994 (9)

3.4               Certificate of Amendment of Certificate of Incorporation filed
                  7/22/1999 (10)

                                       28
<PAGE>

3.5               Certificate of Amendment of Certificate of Incorporation filed
                  8/31/2001 (1)

3.6               Certificate of Amendment of Certificate of Incorporation filed
                  10/30/2002 (2)

3.7               Certificate of Amendment of Certificate of Incorporation filed
                  12/26/2002 (2)

3.8               Certificate of Merger merging Repossession Auction, Inc.
                  (Florida corporation) and Repossession, Inc. (Delaware
                  corporation) (9)

3.9               Certificate of Designations creating Series A Preferred Stock
                  (12)

3.10              Bylaws, as amended and restated (2)

4.1               Form of Warrant to Purchase Common Stock issued to Preferred
                  Stock investors (12)

4.2               Warrant to Purchase Common Stock issued to Arthur Lipper (12)

4.3               Warrant No. AG-1 to purchase up to 6,158,381 shares of NuWay
                  Medical, Inc. common stock held by Augustine II LLC (5)

4.4               Amended and Restated Warrant No. AG-1 to purchase up to
                  6,158,381 shares of NuWay Medical, Inc. common stock held by
                  Augustine II LLC (12)

10.1              Employment Agreement between the Company and Dennis Calvert
                  dated December 11, 2002 (2)

10.2              Employment Agreement between the Company and Joseph Provenzano
                  dated March 1, 2003 (2)

10.3              License Agreement with Med Wireless Inc. dated August 21, 2002
                  (2).

10.4              Amendment to License Agreement with Med Wireless Inc. dated
                  September 18, 2002 (2)

10.5              Secured Promissory Note in the face amount of $1,120,000
                  issued to Med Wireless (4)

10.6              Secured Term Promissory Note in the face amount of $900,000 by
                  New Millennium to Camden Holdings (4)

10.7              Agreement to issue warrant dated February 24, 2003 between
                  NuWay Medical, Inc. and Sachi International, Inc. (12)

10.8              Term Loan Agreement dated as of June 10, 2003 between NuWay
                  Medical, Inc. and Augustine II LLC (5)

10.9              Stock Pledge Agreement dated as of June 10, 2003, between New
                  Millennium and Augustine II LLC (5)

10.10             Stock Pledge Agreement dated as of June 10, 2003, between
                  NuWay Medical, Inc. and Augustine II LLC (5)

                                       29
<PAGE>

10.11             Promissory Note dated November 20, 2003 between NuWay Medical,
                  Inc. and James Seay, DDS. (12)

10.12             Amendment No. 1 to Promissory Note (dated November 20, 2003
                  between NuWay Medical, Inc. and James Seay, DDS) dated
                  February 10, 2005 (14)

10.13             Promissory Note by NuWay Medical, Inc. in favor of Augustine
                  II, LLC (5)

10.14             Amendment No. 1 to Term Loan Agreement dated as of March 30,
                  2004 between NuWay Medical, Inc. and Augustine II LLC (12)

10.15             Amended and Restated Convertible Term Note by NuWay Medical,
                  Inc. in favor of Augustine II, LLC (12)

10.16             Convertible Loan Agreement and Note between NuWay Medical,
                  Inc. and James Burchard (12)

10.17             Conversion Agreement with New Millennium dated October 16,
                  2003 (6)

10.18             Stock Purchase Agreement with Premium Medical Group, Luis Ruiz
                  and Eduardo Ruiz (7)

10.19             Rescission Agreement with Premium Medical Group, Luis Ruiz and
                  Eduardo Ruiz (8)

10.20             Unsecured Promissory Note dated March 7, 2005 in favor of
                  Dennis Calvert (13)

10.21             Form of Convertible Term Note issued in Second Offering (14)

10.22             Second Amended and Restated Convertible Term Note by NuWay
                  Medical, Inc., in favor of Augustine II, LLC (16)

10.23             Amendment Number 2 to Term Loan Agreement dated as of July 29,
                  2005 between NuWay Medical, Inc. and Augustine II, LLC (16)

10.24             Warrant Number AG-II to Purchase Common Stock issued July 29,
                  2005 in favor of Augustine II, LLC (16)

10.25             Marketing and License Agreement (17)

10.26             Form of Promissory Note issued in the Third Offering Note (17)

10.27             Form of Warrant issued in the Third Offering (17)

21.1*             List of Subsidiaries of the Registrant

24.1*             Power of Attorney (included on Signature Page)

31.1*             Certification of Chief Executive Officer Pursuant to Section
                  302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and
                  15(d)-14 under the Securities Exchange Act of 1934

                                       30
<PAGE>


32.1*             Certification of Chief Executive Officer and Interim Chief
                  Financial Officer Pursuant to 18 U.S.C. Section 1350.
-------------------
*    Filed herewith
(1)   Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 2001.
(2)   Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 2002.
(3)   Incorporated herein by reference from the Form S-8 filed by the Company on
      August 8, 2002, and amended on Form S-8 filed by the Company on December
      27, 2002.
(4)   Incorporated herein by reference from the Form 8K filed by the Company on
      May 1, 2003.
(5)   Incorporated herein by reference from the 10-QSB filed by the Company for
      the period ending March 31, 2003.
(6)   Incorporated herein by reference from the Form 8-K filed by the Company on
      October 31, 2003.
(7)   Incorporated herein by reference from the Form 8-K filed by the Company on
      February 17, 2004.
(8)   Incorporated herein by reference from the Form 8-K filed by the Company on
      October 15, 2004.
(9)   Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 1998
(10)  Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 1999
(11)  Incorporated herein by reference from the Form S-8 filed by the Company on
      February 27, 2003.
(12)  Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 2003
(13)  Incorporated herein by reference from the 10-QSB filed by the Company for
      the period ending March 31, 2004.
(14)  Incorporated herein by reference from the 10-KSB filed by the Company for
      the year ended December 31, 2005.
(15)  Incorporated herein by reference from the Form 8-K filed by the Company on
      July 8, 2005.
(16)  Incorporated herein by reference from the 10-QSB filed by the Company for
      the period ending March 31, 2005.
(17)  Incorporated herein by reference from the Form 8-K filed by the Company on
      January 9, 2006.


ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

      The information required by this section is incorporated by reference from
the information in the section entitled "Ratification of Appointment of
Independent Auditor" in the Proxy Statement.



                                       31
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                        NUWAY MEDICAL, INC.


Date: March 31, 2006                    By:  /s/ Dennis Calvert
                                             -------------------------------
                                             Dennis Calvert, President,
                                             Chief Executive Officer and
                                             Interim Chief Financial Officer

                                POWER OF ATTORNEY

      KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints, jointly and severally, Dennis Calvert
and Joseph Provenzano, and each of them, as his or her true and lawful
attorneys-in-fact and agents, with full power of substitution and
resubstitution, for him or her and in his or her name, place and stead, in any
and all capacities, to sign any and all amendments to this Annual Report on Form
10-KSB, and to file the same, with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or any of them, or their or his or her substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.

      Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Company
and in the capacities and on the date indicated:

         NAME                         TITLE                    DATE
--------------------------------------------------------------------------------

   /s/Dennis Calvert          Chairman of the Board,      March 31, 2006
                             Chief Executive Officer,

--------------------------------------------------------------------------------
     Dennis Calvert            President and Chief
                               Financial Officer

  /s/Joseph Provenzano               Director              March 31, 2006
--------------------------------------------------------------------------------
   Joseph Provenzano

/s/Steven V. Harrison II             Director              March 31, 2006
--------------------------------------------------------------------------------
 Steven V. Harrison II

      /s/Gary Cox                    Director              March 31, 2006
--------------------------------------------------------------------------------
        Gary Cox


                                       32

<PAGE>

                          INDEX TO FINANCIAL STATEMENTS



Report of Independent Registered Public Accounting Firm....................F-1

Consolidated Balance Sheets as of December 31, 2005 and
         December 31, 2004.................................................F-2

Consolidated Statements of Operations for the years
         ended December 31, 2005 and 2004..................................F-3

Consolidated Statements of Changes in Stockholders'
         Deficit for the years ended December 31, 2005 and 2004............F-4

Consolidated Statements of Cash Flows for the years
         ended December 31, 2005 and 2004..................................F-5

Notes to Consolidated Financial Statements..........................F-6 - F-28


<PAGE>

             Report of Independent Registered Public Accounting Firm


To the Board of Directors and Stockholders
NuWay Medical, Inc.

      I have audited the consolidated balance sheets of NuWay Medical, Inc. and
Subsidiary (the "Company") as of December 31, 2005 and 2004 and the related
consolidated statements of operations, stockholders' deficit and cash flows for
the years then ended. These consolidated financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these consolidated financial statements based on my audit.

      I conducted my audits in accordance with standards of the Public Company
Accounting oversight Board (United States). Those standards require that I plan
and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement. An audit
includes consideration of internal control over financial reporting as a basis
for designing audit procedure that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the company's
internal control over financial reporting. Accordingly, I express no such
opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosure in the consolidated financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management as well as evaluating the overall financial statement
presentation. I believe my audits provide a reasonable basis for my opinion.

      In my opinion, the consolidate financial statements referred to above
present fairly, in all material respects, the consolidated financial position of
NuWay Medical, Inc. and Subsidiary as of December 31. 2005 and 2004 and the
results of their operations and their cash flows for the years then ended, in
conformity with the accounting principles generally accepted in the United
States of America.

      The accompanying consolidated financial statements have been prepared
assuming the Company will continue as a going concern. As discussed in Note 1 to
the consolidated financial statements, the Company has limited liquid resources,
recurring losses, and is seeking to implement its business plan, which requires
the Company to acquire or develop a business. These matters raise substantial
doubt about its ability to continue as a going concern. Management's plans in
regard to these matters are also discussed in Note 1. The consolidated financial
statements do not include any adjustment that might result from the outcome of
this uncertainty.

/s/ Jeffrey S. Gilbert

Los Angeles, California
March 22, 2006



                                      F-1
<PAGE>



                        NUWAY MEDICAL, INC AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEETS
                        AS OF DECEMBER 31, 2005 AND 2004

<TABLE>
<CAPTION>
                                     ASSETS
                                                                         December 31,       December 31,
                                                                              2005              2004
                                                                         ------------       ------------
<S>                                                                      <C>                <C>
CURRENT ASSETS
      Cash and Cash Equivalents                                          $    283,462       $         --

                                                                         ------------       ------------
                     Total Current Assets                                     283,462                 --
                                                                         ------------       ------------
TOTAL ASSETS                                                             $    283,462       $         --
                                                                         ============       ============

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
      Accounts Payable and Accrued Expenses                              $  2,312,663       $  2,054,270
      Notes Payable                                                         2,740,570          1,632,100
      Debentures Payable, Net                                                  21,151             21,151
                                                                         ------------       ------------
                     Total Current Liabilities                              5,074,384          3,707,521
                                                                         ------------       ------------

COMMITMENTS, CONTINGENCIES AND SUBSEQUENT
EVENTS

SHAREHOLDERS' EQUITY
      Convertible Preferred Series A, $.00067 Par Value, 25,000,000
          Shares Authorized, 559,322  Shares Issued and
          Outstanding at December 31, 2005 and December 31, 2004                  375                375
      Common Stock, $.00067 Par Value, 100,000,000 Shares
           Authorized, 62,453,501 and 51,981,236 Shares Issued
           At December 31, 2005 and December 31, 2004, respectively            41,136             34,120
      Additional Paid-In Capital                                           23,396,754         23,299,870
      Accumulated Deficit                                                 (28,229,187)       (27,041,886)
                                                                         ------------       ------------
                     Total Shareholders' Equity                            (4,790,922)        (3,707,521)
                                                                         ------------       ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                               $    283,462       $         --
                                                                         ============       ============
</TABLE>


          See accompanying notes to consolidated financial statements

                                      F-2
<PAGE>

                       NUWAY MEDICAL, INC AND SUBSIDIARY
                  STATEMENTS OF OPERATIONS FOR THE YEARS ENDED
                           DECEMBER 31, 2005 AND 2004

<TABLE>
<CAPTION>
                                                                    2005           2004
                                                               ------------    ------------
<S>                                                            <C>             <C>
Revenue                                                        ------------    ------------
                        Total Revenues                                   --              --
                                                               ------------    ------------
Costs and Expenses
       Selling, General and Administrative                     $    944,807    $    971,944
       Depreciation, Depletion and Amortization                          --              --
                                                               ------------    ------------
                        Total Costs and Expenses                    944,807         971,944
                                                               ------------    ------------
Loss from operations                                               (944,807)       (971,944)
                                                               ------------    ------------
Other Income and Expense
       Interest Expense                                            (242,494)       (250,704)
       Other Income                                                      --           4,600
                                                               ------------    ------------
                        Net Other Expense                          (246,104)       (246,104)
                                                               ------------    ------------

                                                               ------------    ------------
Net Loss                                                       $ (1,187,301)   $ (1,218,048)
                                                               ============    ============
Loss Per Common Share - Basic and Diluted
       Loss per share                                          $      (0.02)   $      (0.03)
                                                               ============    ============
       Weighted Average Common Share Equivalents Outstanding     54,041,809      45,987,808
                                                               ============    ============
</TABLE>

          See accompanying notes to consolidated financial statements



                                      F-3
<PAGE>

                        NUWAY MEDICAL, INC AND SUBSIDIARY
                       STATEMENTS OF STOCKHOLDERS' DEFICIT
                 FOR THE YEARS ENDED DECEMBER 31, 2004 AND 2005

<TABLE>
<CAPTION>
                                  Preferred Stock                Common Stock
                               -----------------------   ------------------------------
                                Number          Par           Number           Par          Additional       Retained
                                  of           Value            of            Value          Paid-In         Earnings      Treasury
                                Shares        $.00067         Shares         $.00067         Capital         (Deficit)       Stock
                               ----------     --------   --------------  ------------    -------------   ---------------  ----------
<S>                            <C>              <C>         <C>              <C>          <C>             <C>              <C>
BALANCE DECEMBER 31, 2003        559,322          375       36,386,486   $    23,976      $23,002,818     $(25,823,838)   $(127,004)

STOCK ISSUED FOR SERVICES                                    9,183,400         6,181         362,885

CONVERSION OF
    DEBENTURES                                               1,100,000           405          34,595

RETIREMENT OF TREASURY STOCK                                  (44,900)           (30)       (126,974)                        127,004

SALE OF COMMON STOCK                                         5,156,250         3,454          26,546

ADJUSTMENT TO COMMON STOCK                                     200,000           134

  NET LOSS FOR THE YEAR
  ENDED DECEMBER 31, 2003                                                                                   (1,218,048)
                               ----------     --------   --------------  ------------    -------------   ---------------  ----------
BALANCE DECEMBER 31, 2004        559,322          375       51,981,236        34,120        23,299,870      (27,041,886)           -


ADJUSTMENT TO COMMON STOCK                                      82,265            55             (55)

STOCK ISSUED FOR SERVICES                                   10,390,000         6,961           96,939

NET LOSS                                                                                                    (1,187,301)
                               ----------     --------   --------------  ------------    -------------   ---------------  ----------
BALANCE DECEMBER 31, 2005        559,322      $   375       62,453,501     $  41,136      $23,396,754     $(28,229,187)   $        -
                               ==========     ========   ==============  ============    =============   ===============  ==========
</TABLE>

          See accompanying notes to consolidated financial statements



                                      F-4
<PAGE>

                        NUWAY MEDICAL, INC AND SUBSIDIARY
                  STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED
                           DECEMBER 31, 2005 AND 2004

<TABLE>
<CAPTION>
                                                                                -----------    -----------
                                                                                    2005           2004
                                                                                -----------    -----------
<S>                                                                             <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Net Loss                                                                      $(1,187,301)   $(1,218,048)
  Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
        Issuance of Stock for Services                                              103,900        362,898
        Amortization of Discount on Note                                                 --         62,131
        Increase in Accounts Payable and Accrued Expenses                           258,393        725,248
                                                                                -----------    -----------
      Net Cash Used In Operating Activities                                        (825,008)       (67,771)
                                                                                -----------    -----------

CASH FLOWS FROM INVESTING ACTIVITIES
                                                                                -----------    -----------
      No Cash Used In or Provided by Investing Activities                                --             --
                                                                                -----------    -----------

CASH FLOWS FROM FINANCING ACTIVITIES
      Funds from Loan                                                             1,108,470         60,000
      Payments to reduce Note Payable                                                    --        (22,900)
      Proceeds from Sale of Common Stock                                                 --         30,000
      Proceeds from Sale of Preferred Stock                                              --             --
                                                                                -----------    -----------
      Net Cash Provided By Financing Activities                                   1,108,470         67,100
                                                                                -----------    -----------

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS                                283,462           (671)

CASH AND CASH EQUIVALENTS - BEGINNING                                                    --            671
                                                                                -----------    -----------

CASH AND CASH EQUIVALENTS - ENDING                                              $   283,462    $        --
                                                                                ===========    ===========

SUPPLEMENTAL DISCLOSURES OF CASHFLOW INFORMATION

Cash Paid During the Period for:
  Interest
                                                                                $        --    $        --
                                                                                ===========    ===========
  Income Taxes                                                                  $        --    $        --
                                                                                ===========    ===========
</TABLE>

           See accompanying notes to consolidated financial statements



                                      F-5
<PAGE>

                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS




NOTE 1. BUSINESS AND ORGANIZATION



      OUTLOOK

      The Company had no continuing business operations as of December 31, 2005.
The Company operated as a public shell during the twelve month period ended
December 31, 2005, and operations primarily consisted of the Company's president
seeking funding, maintaining the corporate entity, complying with the
requirements of the Securities Exchange Commission (the "SEC") and seeking
merger and acquisition candidates or new business opportunities. (See discussion
of the letter of intent with IOWC Technologies, Inc. ("IOWC"), in Note 5.)

      The Company will need working capital resources to maintain the Company's
status and to fund other anticipated costs and expenses during the year ending
December 31, 2005 and beyond, as well as to consummate the transactions with
IOWC and fund the operations of the Company after the transactions are
consummated. The Company's ability to continue as a going concern is dependent
on the Company's ability to raise capital to, at a minimum, meet its corporate
maintenance requirements. If the Company is able to acquire IOWC or another
ongoing business and/or technology that must be exploited, it would need
additional capital until and unless that prospective operation is able to
generate positive working capital sufficient to fund the Company's cash flow
requirements from operations.

      Cash and cash equivalents totaled $283,462 at December 31, 2005. The
Company had no revenues in the twelve-month period ended December 31, 2005 and
was forced to consume cash on hand to fund operations. The Company will be
required to raise additional capital to sustain basic operations through the
remainder of 2006 and to consummate the transactions with IOWC. While the
Company is actively seeking investments through private investors and other
parties, there is no assurance that the Company will be able to raise additional
capital for the entire period required.

      The Company has approximately $2,740,570 aggregate principal amount of its
promissory notes that mature at various times during 2006. The Company does not
presently have funds sufficient to repay these obligations as they mature. Even
though the terms of all of these notes permit the noteholder to convert the
notes into shares of our common stock, until the Company's stockholders approve
an amendment to the Company's charter to increase the number of authorized
shares of common stock, the Company will be unable to fulfill its obligations to
all noteholders to permit the conversion into common stock of amounts due
pursuant to the terms of the notes. In the event that the Company has not raised
further capital prior to the maturity dates of the convertible notes, the
Company would be in default of those notes if its stockholders have not formally
approved an increase in the number of authorized common shares, or unless the
Company is able to refinance or renegotiate the terms of these notes. No
financing is in place at present, and it is unknown if any financing will be in
place in the future, which would permit the Company to repay these notes in full
as they mature.

                                      F-6
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The financial statements accompanying this Annual Report have been
prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of our
business. As reflected in the accompanying financial statements, the Company had
a net loss of $1,187,301 for the twelve-month period ended December 31, 2005,
negative cash flow from operating activities of $825,008 for the twelve-month
period ended December 31, 2005, and a stockholders' deficiency of $28,229,187 as
of December 31, 2005. Also, as of December 31, 2005, the Company had limited
liquid and capital resources. The foregoing factors raise substantial doubt
about the Company's ability to continue as a going concern. Ultimately, the
Company's ability to continue as a going concern is dependent upon its ability
to attract new sources of capital, establish an acquisition or reverse merger
candidate with continuing operations, such as IOWC, attain a reasonable
threshold of operating efficiencies and achieve profitable operations. The
financial statements do not include any adjustments that might be necessary if
the Company is unable to continue as a going concern.

      During 2005, the Company raised $1,055,620 gross proceeds ($1,035,370 net
proceeds) in three private offerings. This amount consisted of (i) $25,000 gross
proceeds which was raised in a private offering (the First Offering) of
convertible notes that commenced in October 2004 and terminated in January 2005;
(ii) $756,120 gross proceeds ($735,870 net proceeds) which was raised in a
private offering (the Second Offering) of convertible notes that commenced in
January 2005 and terminated in August 2005; and (iii) $299,500 gross and net
proceeds which was raised in a private offering (the Third Offering) of
convertible notes that commenced in September 2005 and terminated in February
2006.

      In the First Offering, the Company offered 10% convertible notes (the
First Offering Notes) due and payable one year from the date of issuance. The
First Offering Notes bear interest at a rate of 10% per annum, payable on the
maturity date, and can be converted, in whole or in part, into shares of the
Company's preferred stock, on a basis of $.005 per share, at any time prior to
maturity by either the Company or the holder. See Part II, Item 5 "Sales of
Unregistered Securities".

      In the Second Offering, the Company offered 10% convertible notes (the
Second Offering Notes) due and payable one year from the date of issuance. The
Second Offering Notes bear interest at a rate of 10% per annum, payable on the
maturity date, and can be converted, in whole or in part, into shares of the
Company's common stock, on a basis of ranging from $.005 to $0.016 per share, at
any time prior to maturity by either the Company or the holder. See Part II,
Item 5 "Sales of Unregistered Securities".

                                       F-7
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      In the Third Offering, the Company offered up to $1 million of its 10%
convertible notes due October 31, 2006 (the Third Offering Notes) and stock
purchase warrants (the Third Offering Warrants) to purchase up to an aggregate
40,000,000 shares of the Company's common stock. The Third Offering Notes are
convertible into shares of common stock at $.025 per share. The Third Offering
Warrants are exercisable at a price of $.05 per share and expire on October 31,
2007. The Second Offering was made to a limited number of individuals who are
"accredited investors" as that term is defined by Rule 501(a) of Regulation D
promulgated under the Securities Act of 1933, as amended (the "Securities Act").
The Company amended the terms of the Third Offering to increase the amount of
the offering to up to $2 million, extend the expiration of the offering, extend
the maturity date of the Third Offering Notes to January 31, 2007, and extend
the expiration of the Third Offering Warrants to January 31, 2008. The Third
Offering terminated on February 21, 2006, by which date the Company had raised
$1,102,000 gross and net proceeds. Of this amount, $299,500 was raised during
2005.

      Even with the successful completion of the Third Offering, the Company
will be required to raise additional capital to sustain its operations and meet
its liabilities as they become due for the next twelve months, as well as to
consummate the transactions with IOWC, fund the operations of the Company after
the transactions are consummated and meet its obligations, including the First
Offering Notes, the Second Offering Notes, and the Third Offering Notes, as they
mature.

      ORGANIZATION

      The Company was initially organized as Repossession Auction, Inc. under
the laws of the State of Florida in 1989. In 1991, the Company merged into a
Delaware corporation bearing the same name. In 1994, the Company's name was
changed to Latin American Casinos, Inc. to reflect its focus on the gaming and
casino business in South and Central America, and in 2001 the Company changed
its name to NuWay Energy, Inc. to reflect its new emphasis on the oil and gas
development industry. During October 2002, the Company's name was changed to
NuWay Medical, Inc. coincident with the divestiture of its non-medical assets
and the retention of new management.

      PROPOSED ACQUISITION OF IOWC ASSETS

      On July 25, 2005, the Company executed a letter of intent ("LOI") with
IOWC, pursuant to which the Company will acquire certain of BioLargo's assets
(the "Purchased Assets"), consisting of certain intellectual property, including
two United States patents (collectively, the "BioLargo Technology"), and two
license and/or distributor agreements pursuant to which IOWC has licensed the
BioLargo Technology for use in products designed for distribution in the food,
medical and biohazardous material transportation industries. All assets not
constituting the Purchased Assets will remain the property of BioLargo following
the closing. The Company will not assume any liabilities of BioLargo.

                                       F-8
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The parties also agreed that on or prior to the closing, they would enter
into a definitive asset purchase agreement (the "Asset Purchase Agreement"), and
other agreements, including a research and development agreement (the "R&D
Agreement"), to effect the transactions on or prior to the closing. Pursuant to
the R&D Agreement, the Company will pay BioLargo a monthly fee to conduct
research to further develop the existing BioLargo Technology and products based
on the existing and new technologies.

      The letter of intent also requires the Company to raise sufficient funds
to (i) cover the costs of the transactions, (ii) three months post-closing
operating expenses, the latter of which is estimated at approximately $300,000
and (iii) provide interim funding to BioLargo on a best efforts basis and in
amounts agreed between the parties in an aggregate amount not to exceed
$1,000,000.

      The letter of intent further provides that, at the Closing, the Company
and Dennis Calvert will enter into an employment agreement for a term of five
years, providing Mr. Calvert with a monthly salary of $15,400 for 2006, and a
10% increase in his monthly salary for each calendar year thereafter.

      It is anticipated that the present management of the Company will remain
in place after the closing and that Mr. Code will become the Company's Chief
Technology Officer. In connection therewith, Mr. Code will enter into an
employment agreement with the Company (the "Code Employment Agreement").

      In connection with the previously described transactions and in partial
implementation thereof, on December 31, 2005, the Company executed a Marketing
and Licensing Agreement ("M&L Agreement") with BioLargo. Pursuant to the M&L
Agreement, the Company, through its wholly-owned subsidiary BioLargo Life
Technologies, Inc., a California corporation formed January 3, 2006 ("BLTI"),
acquired certain rights ("Rights") from BioLargo to develop, market, sell and
distribute products that were developed, and are in development, by BioLargo
using the BioLargo Technology.

      BioLargo also assigned to BLTI its rights and obligations under two
license agreements, including BioLargo, LLC, in which BioLargo has a 20%
interest, as well as its rights set forth in a letter of intent with another
entity (collectively, the "Assigned Agreements"). The M&L Agreement provides
that the Company is to receive any and all royalties, payments, license fees,
and other consideration generated by the Assigned Agreements. As part of the M&L
Agreement, IOWC has agreed to transfer its 20% interest in BioLargo, LLC to the
Company. In consideration of the Rights and the Assigned Agreements, the Company
has agreed to issue IOWC a total of 38% of its common stock.

                                       F-9
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The parties further agreed to enter into additional agreements in
furtherance of the July 2005 letter of intent between the Company and IOWC,
including (i) the Asset Purchase Agreement, whereby the Company would acquire
the two U.S. patents held by IOWC; (ii) the R&D Agreement, with a company to be
managed and controlled by Mr. Code; and (iii) the Code Employment Agreement. In
consideration of the Asset Purchase Agreement, the Company has agreed to issue
IOWC an additional one percent of its common stock. In consideration of the R&D
Agreement and Code Employment Agreement, the Company has agreed to issue to Code
individually 17.6% of its common stock. As a result of the foregoing
transactions, the Company will issue a total of 56.6% of its common stock to
BioLargo, calculated on January 1, 2006. The parties further agreed that to the
extent that the Company issues additional equity in connection with one or more
financing transactions after January 1, 2006, then the percentage of equity to
be issued to BioLargo would be diluted pro rata.

      The Code Employment Agreement is anticipated to provide that Mr. Code will
be appointed Chief Technology Officer of BLTI, and receive a monthly salary of
$15,400. As explained below, the Company is required to obtain the approval of
its stockholders prior to the issuance of the common stock to IOWC required
pursuant to the M&L Agreement.

      The foregoing transactions are subject to approval by IOWC's board of
directors and stockholders, approval by the Company's board of directors, and
approval by the Company's stockholders of the following matters:

      o     an amendment to the Company's Certificate of Incorporation
            increasing the number of authorized shares of its common stock;

      o     the issuance of the number of shares of common stock to IOWC
            required pursuant to the Transactions;

      o     a reverse split of the Company's common stock; and

      o     the election of Mr. Code to the Company's board of directors.

      In the event that the Company's stockholders do not approve the issuance
of stock, the M&L Agreement shall terminate, and all rights granted to the
Company shall revert to BioLargo.

      The closing of the transactions is subject to various conditions,
including those described hereinabove, and conditions customary for transactions
of this nature.


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

      a) Principles of Consolidation.

      The Company has one subsidiary which is inactive called NuWay Sports, LLC.
Management has not been able to sell it. There are no other subsidiaries. The
consolidated balance sheets include the accounts of NuWay Medical, Inc. and
NuWay Sports, LLC. All significant inter-company balances have been eliminated
in consolidation.

                                       F-10

<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      b) Property and Equipment.

      On April 1, 2004 the Company closed its offices and has in storage its
furniture, fixtures and office equipment. While in use, depreciation was
provided on a straight-line basis over the estimated useful life of the
respective asset. Maintenance and repairs was charged to expense as incurred.
There were no major renewals or betterments.

      c) Impairment of Long-Lived Assets.

      The Company periodically reviews its long-lived assets for potential
impairment as required by Statement of Financial Accounting Standards No. 144,
"Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
be Disposed of."

      d) Earnings (Loss) Per Share.

      The Company reports basic and diluted earnings (loss) per share (EPS) for
common and common share equivalents. Basic EPS is computed by dividing reported
earnings by the weighted average shares outstanding. Diluted EPS is computed by
adding to the weighted average shares the dilutive effect if stock options and
warrants were exercised into common stock. For the years ended December 31, 2005
and 2004, the denominator in the diluted EPS computation is the same as the
denominator for basic EPS due to the anti-dilutive effect of the warrants and
stock options on the Company's net loss.

      For the years ended December 31, 2005 and 2004, the computation of basic
EPS is as follows:

                                               2005                   2004
                                       ------------------     -----------------
Numerator - net loss                   $      (1,187,301)     $     (1,218,048)
                                       ==================     =================
Denominator - weighted shares
  outstanding                                 54,041,809            45,987,808
                                       ------------------     -----------------
Loss per share from Continuing
  Operations                           $           (0.02)     $          (0.03)
                                       ==================     =================

      e) Use of Estimates.

      The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities, the disclosure of contingent assets and liabilities at
the date of the financial statements, and revenues and expenses during the
period reported. Actual results could differ from those estimates. Estimates are
used when accounting for stock-based transactions, uncollectible accounts
receivable, asset depreciation and amortization, and taxes, among others.

                                       F-11
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      f) Stock Options and Warrants issued for Services.

      As permitted under the Statement of Financial Accounting Standards No. 123
(SFAS No. 123), "Accounting for Stock-Based Compensation," the Company accounts
for its stock-based compensation to employees in accordance with the provisions
of Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock
Issued to Employees," and related interpretations. The Company provides the pro
forma net earnings, pro forma earnings per share, and stock based compensation
plan disclosure requirements set forth in SFAS No. 123.

      In December 2004, the Financial Accounting Standards Board ("FASB") issued
FASB Statement No. 123 (Revised 2004), "Share-Based Payment" ("SFAS No.123(R)").
SFAS No. 123(R) replaces SFAS No. 123 "Accounting for Stock-Based Compensation",
which supersedes Accounting Principles Board ("APB") Opinion No. 25 "Accounting
for Stock Issued to Employees", ("APB 25"), and amends FASB Statement No 95,
"Statement of Cash Flows". SFAS No. 123 (R) requires all share-based payments to
employees, including grants to employee stock options, to be recognized in the
financial statements based on their fair values. SFAS No. 123(R) is effective
for the first annual reporting period beginning after June 15, 2005. The Company
does not expect the impact of the adoption of SFAS 123(R) to have a material
effect on the Company's results of operations.

      For stock issued to consultants and other non-employees for services, the
Company records the expense based on the fair market value of the securities as
of the date of the stock issuance.

      g) Non-Cash Transactions

      The Company has established a policy relative to the methodology to
determine the value assigned to each intangible acquired with or licensed by the
Company and/or services or products received for non-cash consideration of the
Company's common stock. The value is based on the market price of the Company's
common stock issued as consideration, at the date of the agreement of each
transaction or when the service is rendered or product is received, as adjusted
for applicable discounts.

      The methods, estimates and judgments the Company uses in applying these
most critical accounting policies have a significant impact on the results of
the Company reports in its financial statements.



NOTE 3. WARRANTS


      During 2005, the Company issued warrants purchase total of 19,980,000
shares of the Company's common stock. Warrants to purchase 8,000,000 shares of
the Company's common stock were issued to the Augustine Fund as consideration
for the extension of the maturity date of the Augustine Loan. (See Note 8.)
These warrants allow for the holder to purchase shares of common stock at an
exercise price of $0.005 per share through July 29, 2010. Warrants to purchase
11,980,000 shares of the Company's common stock were issued in a private
offering to twelve investors. These warrants allow for the holder to purchase
shares of common stock at an exercise price of $0.05 per share through January
31, 2008. The value of the warrants at the time of issuances were immaterial as
the exercise price was equal to or greater than the market price of the common
shares at that time.

                                       F-12
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      During 2003, the Company issued warrants to purchase a total of 7,011,036
shares of the Company's common stock on the following terms: (i) 120,000 shares
to an investor in connection with a purchase of the Company's preferred stock,
at a price of $0.20 per share, which expires March 7, 2006 (ii) 399,322 shares
to investors in connection with a purchase of the Company's preferred stock, at
a price of $0.20 per share, which expires April 15, 2006; (iii) 6,158,381 shares
to an investor in connection with a loan to the Company, originally at a price
of $0.16 per share, which price adjusted to $0.035 per share in connection with
an extension of the loan repayment obligation, which expires June 10, 2008; (iv)
333,333 shares to a consultant in connection with consulting services, at a
price of $0.06 per share, which expires August 29, 2008. The compensation
expense related to (iv) above is immaterial.

      In December 2000, the board of directors authorized the issuance of
3,300,000 private five-year stock warrants to acquire common stock at $1.75 per
share. 1,500,000 of these warrants as well as 200,000 shares of restricted stock
were issued to the then existing executive officers. In February 2002, 3,000,000
of the 3,300,000 warrants issued in year 2000 were cancelled. The remaining
300,000 warrants expired unexercised in 2005.



NOTE 4. STOCK COMPENSATION PLANS



      NUWAY MEDICAL, INC. 2004 EQUITY PLAN

      On March 10, 2004, the board of directors approved the Company's 2004
Equity Plan as a means of providing directors, key employees and consultants
additional incentive to provide services for the Company. Both stock options and
stock grants may be made under this plan. The Plan sets aside up to 20,000,000
shares of the Company's common stock for these purposes, which were registered
with the SEC. Approval of this plan was not submitted to the vote of the
shareholders. The Board administers this plan. The plan allows the Board to
award grants of common shares or options to purchase common shares. As plan
administrator, the board has sole discretion to set the price of the options.
The Board may at any time amend or terminate the plan. It does not expire on its
terms.

                                       F-13
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      During 2004, the Company issued approximately 9,180,000 shares to 16
consultants, directors, and employees. Of this total 5,680,000 have been
registered with the SEC, while the balance, 3,500,000 shares were not registered
and are restricted securities. Of the total issued in 2004, 1,580,000 shares
relate to services performed in 2003 and 7,600,000 shares relate to 2004. The
effect of the shares issued for 2003 services in 2004 was accrued in the
Company's financial statements for the year ending December 31, 2003. In 2004
there were $275,400 of expenses recorded related to the issuance of these
shares. Of this amount $120,000 related to consulting services, $5,400 related
to legal services, $60,000 related to Board of Directors expense, and $90,000
related to salary expense.

      During 2005, the Company issued no shares under the plan.



NOTE 5. SALE OF UNREGISTERED SECURITIES


      FIRST OFFERING

      In January 2005, pursuant to a private offering that commenced in October
2004 and terminated in January 2005 (the "First Offering"), the Company received
gross and net proceeds of $25,000 from an outside investor and issued its
convertible promissory note (the "First Offering Note") due and payable one year
from the date of issuance. The First Offering Note bears interest at a rate of
10% per annum, payable on the maturity date. The First Offering Note can be
converted, in whole or in part, into shares of the Company's Series A Preferred
stock, on the basis of $.005 per share, at any time prior to maturity by either
the Company or the lender. Each share of Series A Preferred Stock may be
converted by the holder into one share of the Company's common stock. If the
noteholder converts the First Offering Note into Series A Preferred Stock, on or
after the note's original maturity date the noteholder may require the Company
to buy back the shares of Series A Preferred Stock for 110% of the principal
amount of the note (the "Buy Back Provision"). If the Company is unable to do
so, the Company's president, Dennis Calvert, has agreed to buy back the shares
on the same terms. If shares of Series A Preferred Stock are converted into
common stock, the holder has the right to include (piggyback) the shares of
common stock in a registration of securities filed by the Company, other than on
Form S-4 or Form S-8.

      The Company's payment obligations under the First Offering Note may be
accelerated upon the following events: (i) the sale of the Company's assets
outside the ordinary course of business; (ii) a breach of the representations
and warranties contained within the evidencing the loan; (iii) the failure to
timely pay the note; (iv) the Company's default in any other loan obligation
greater than $100,000; (v) the Company's dissolution, liquidation, merger,
consolidation, bankruptcy, or future insolvency; and (vi) the commencement of
any suit that threatens to have a material adverse effect on the Company,
including the entry of a final judgment or settlement in excess of $100,000.

                                       F-14
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      SECOND OFFERING

      In January 2005, pursuant to a private offering that commenced in that
month and terminated in August 2005 (the "Second Offering"), the Company
received gross and net proceeds of $75,000 from two outside investors and issued
its convertible promissory note (the "Second Offering Note") due and payable one
year from the date of issuance. The Second Offering Note bears interest at a
rate of 10% per annum, payable on the maturity date. The Second Offering Note
can be converted, in whole or in part, into shares of the Company's common
stock, on the basis ranging from $.005 to $0.016 per share, at any time prior to
maturity by either the Company or the holder. The holder has the right to
include (piggyback) the shares of common stock in a registration of securities
filed by the Company, other than on Form S-4 or Form S-8.

      The Company's payment obligations under the Second Offering Note may be
accelerated upon the following events: (i) the sale of the Company's assets
outside the ordinary course of business; (ii) a breach of the representations
and warranties contained within the evidencing the loan; (iii) the failure to
timely pay the note; (iv) the Company's default in any other loan obligation
greater than $100,000; (v) the Company's dissolution, liquidation, merger,
consolidation, bankruptcy, or future insolvency; and (vi) the commencement of
any suit that threatens to have a material adverse effect on the Company,
including the entry of a final judgment or settlement in excess of $100,000.

      In February 2005, the Company received gross proceeds of $51,000 and net
proceeds of $47,000 from four outside investors and issued Second Offering Notes
which allow conversion into an aggregate total of 5,558,036 shares of common
stock (at a conversion price of approximately $0.009 per common share).

      In April 2005, the Company received gross proceeds of $29,000 and net
proceeds of $23,750 from two outside investors and issued Second Offering Notes
which allow conversion into an aggregate total of 2,500,000 shares of common
stock (at a conversion price of approximately $0.009 per common share).

      In May 2005, the Company received gross and net proceeds of $50,000 and
$47,500 from an outside investor and issued a Second Offering Note which allows
conversion into a total of 7,142,857 shares of common stock (at a conversion
price of $0.007 per common share).

      In June 2005, the Company received gross and net proceeds of $256,120 from
eleven outside investors and issued Second Offering Notes which allow conversion
into an aggregate total of 28,612,000 shares of common stock (at a weighted
average conversion price of approximately $0.009 per common share).

      Also in July 2005, the Company received gross proceeds of $10,000 and net
proceeds of $9,500 from an outside investor and issued a Second Offering Note
which allows conversion into an aggregate total of 625,000 shares of common
stock (at a conversion price of $0.016 per common share).

                                       F-15
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

         In August 2005, the Company received gross proceeds of $260,000 and net
proceeds of $252,000 from five outside investors and issued Second Offering
Notes which allow conversion into an aggregate total of 16,250,000 shares of
common stock (at a conversion price of $0.016 per common share).

      THIRD OFFERING

      Pursuant to another private offering that commenced in September 2005 and
terminated in February 2006, on December 31, 2005, the Company sold an aggregate
amount of $299,500 of its promissory notes (the "Third Offering Notes") due and
payable January 31, 2007 to twelve individual investors. Each Third Offering
Note bears interest at a rate of 10% per annum, and can be converted, in whole
or in part, into shares of the common stock of the Company at an initial
conversion price of $0.025 per share. The Company sold additional notes under
this offering subsequent to December 31. 2005 (see Note 15 - Subsequent Events).

      The Third Offering Notes may not be converted by either the Company or the
holder unless and until each of the following events has first occurred: (i) the
Company's stockholders have approved an increase in the number of shares of
common stock authorized by the Company's Certificate of Incorporation in an
amount not less than the amount required to permit all notes and warrants issued
in this series to be converted into shares of the Company's Common Stock as
provided herein, at a validly held meeting of stockholders at which a quorum is
present and acting throughout; and (ii) the Company has filed with the Secretary
of State of State of Delaware a Certificate of Amendment to the Company's
Certificate of Incorporation to amend its Certificate of Incorporation to
increase the number of shares of common stock authorized by the Company's
Certificate of Incorporation.

      Purchasers of the Third Offering Notes received, for no additional
consideration, a stock purchase warrant (the "Third Offering Warrant") entitling
the holder to purchase a number of Shares of Common Stock equal to the number of
Shares of Common Stock into which the Third Offering Note is convertible. The
Third Offering Warrant is exercisable at an initial price of $0.05 per Share and
will expire on January 31, 2008.

      OTHER ISSUANCES

      In July 2005, the board of directors of the Company approved the issuance
of 6,000,000 shares of the Company's common stock to two directors and one
officer. An aggregate $20,000 owed by the Company to two independent directors
for unpaid compensation for serving on the board of directors was paid by the
issuance of an aggregate 2,000,000 shares of the Company's common stock, at a
share price of $0.01 per share; and $40,000 owed by the Company to an officer of
the Company for accrued and unpaid compensation, was paid by the issuance of an
aggregate 4,000,000 shares of the Company's common stock, at a share price of
$0.01 per share.

                                       F-16
<PAGE>

                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      Also in July 2005, the Company's board of directors approved the issuance
of an aggregate of 4,390,000 shares of the Company's common stock to two
consultants, at a share price of $0.01 per share. This issuance was in
satisfaction of an aggregate of $43,900 owed by the Company for services
previously performed by these individuals.

      All of these offerings and sales were made in reliance on the exemption
from registration contained in Section 4(2) of the Securities Exchange Act
and/or Regulation D promulgated thereunder as not involving a public offering of
securities.

      Until the Company's stockholders approve an amendment to the Company's
charter to increase the number of authorized shares of common stock, the Company
will be unable to fulfill its obligations to all convertible noteholders to
permit the conversion into common stock of amounts due pursuant to the terms of
the convertible notes. In the event that the Company has not raised further
capital prior to the maturity dates of the convertible notes, the Company would
be in default of those notes if its stockholders have not formally approved an
increase in the number of authorized common shares. The Company is not, at this
time, in default of the convertible notes.


NOTE 6. TERMS OF PREFERRED SHARES

      Each share of the Series A Preferred Stock is convertible into one share
of the Company's common stock. In addition, for each share of preferred stock
sold, the purchaser received one warrant to purchase one share of common stock
at a price of $0.20 per share. The Series A Preferred Stock may be converted by
the holder, at any time after six months from the purchase date and the warrant
is exercisable for a period of three years from the purchase date. The Series A
Preferred Stock vote with the holders of the outstanding shares of Common Stock
and not as a separate class or series, except as may be required by law.

      The holders of outstanding shares of Series A Preferred Stock (which may
be referred to as the "Series A Preferred Stock") shall be entitled to receive
in any fiscal year, dividends, if, when and as declared by the Board of
Directors, out of any assets at the time legally available therefore in cash at
a rate equal to 7% per share, per annum, of the original liquidation preference
of $2.00 per share, subject to adjustment as provided herein. There have been no
dividends declared by the Board of Directors of the Company.



NOTE 7. CONVERTIBLE DEBENTURES


      In December 2000, the Company, through a private placement, issued
$3,500,000 principal amount of 6 percent Convertible Debentures to several
investors. These debentures were originally due June 13, 2001 and their maturity
date was subsequently extended to December 13, 2001. They are convertible into
common stock at a price of $1.75 per share. The interest on the debentures is
payable either in cash or shares of common stock, at the discretion of the
Company. During 2001, $1,100,000 of the debentures plus accrued interest was
converted into 666,283 shares of the Company's common stock. During 2002,
$2,250,000 of the remaining debentures plus accrued interest was converted into
1,332,570 shares of common stock.

                                       F-17
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      In December 2002 the Company received a notice from the remaining two
debenture holders (the "Remaining Debenture Holders") requesting conversion of
the remaining outstanding $150,000 of debentures. The notice provided that, as a
condition to conversion, the certificates representing the shares issuable upon
conversion of the debentures would need to be delivered to the Remaining
Debenture Holders prior to the end of 2002. Pursuant to the request, and to
complete the conversion, the Company issued to the Remaining Debenture Holders
96,006 shares of common stock and promptly notified the Remaining Debenture
Holders' counsel and the Company's transfer agent of the approval and
ratification of the issuance. However, the actual certificates representing the
shares were not delivered to the Remaining Debenture Holders until the first
quarter of 2003. The Remaining Debenture Holders then refused acceptance of the
shares, claiming that because the actual certificates representing the shares
were not delivered in 2002 as specified in the conversion notice, the conversion
was invalid and the debentures would therefore remaining outstanding and
continue to accrue interest until repaid in full. The Remaining Debenture
Holders then demanded full payment on their $150,000 of debentures (plus accrued
interest).

      In June 2003, the Remaining Debenture Holders filed suit in the Orange
County Superior Court against the Company claiming it breached the debenture
agreement by failing to honor the terms of the notice of conversion. The Company
and the Remaining Debenture Holders then entered into a settlement agreement in
which the Remaining Debenture holders would convert the debentures into common
stock equal to approximately $70,000. The settlement agreement called for
conversion into stock over a period of three months. The Company had partially
satisfied the obligations under this agreement as of December 31, 2003, and
further satisfied its obligations in 2004. As of December 31, 2005,
approximately $21,000 remains outstanding.



NOTE 8. LOAN AGREEMENT - AUGUSTINE LOAN


      On June 10, 2003 the Company entered into a Term Loan Agreement ("Loan
Agreement") with Augustine II, LLC ("Augustine Fund"), pursuant to which
Augustine Fund agreed to loan the Company $420,000, payable in installments of
$250,000, $100,000, and $70,000 (the "Augustine Loan"). The Company received all
scheduled installments, and principal and interest (at an annual rate of 10%)
were originally due in full on February 29, 2004. As additional consideration
for making the Augustine Loan, Augustine Fund received five year warrants to
purchase up to 6,158,381 shares of the Company's common stock at an exercise
price of $0.16 per share. The Company can require that the warrants be exercised
if the Company's shares trade at or above $0.60 per share for each trading day
within the 30 calendar days prior to the maturity date of the Augustine Loan,
trading volume of the shares equals or exceeds 100,000 shares per day during
such period, and the shares of the Company's common stock underlying the
warrants have been included on a registration statement filed with and declared
effective by the SEC prior to the maturity date. If these conditions are not
fully satisfied by the maturity date, then Augustine Fund may, at any time
following the maturity date and so long as the warrants remain exercisable,
elect to exercise all or any portion of the warrants pursuant to the "cashless
exercise" provisions of the warrants.

                                       F-18
<PAGE>

                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      In March 2004, Augustine Fund agreed to extend the maturity date of the
Loan Agreement to August 2004. In consideration of the extension, Augustine Fund
was given the option of having the Augustine Loan satisfied in cash or by the
conversion of any remaining principal balance and any accrued interest on the
Augustine Loan to shares of the Company's common stock at a 15% discount to
market, so long as Augustine Fund's holdings do not exceed 4.9% of the total
issued and outstanding shares of the Company's common stock at any time. In
addition, the warrants held by the Augustine Fund to purchase 6,158,381 shares
of the Company's common stock were re-priced to an exercise price of $.035 per
share. Exercise of the warrants is also subject to the limit that the Augustine
Fund does not hold more than 4.9% of the issued and outstanding shares of the
Company's common stock.

      On March 7, 2005, the Company and the Augustine Fund agreed to extend the
maturity date of the Augustine Loan to May 2006 in exchange for the issuance of
a warrant that gives the Augustine Fund the right to purchase 8,000,000 shares
of the Company's common stock at $0.005 per share for a period of five years. On
July 29, 2005, the Company and the Augustine Fund finalized the terms of this
amendment to the Augustine Loan and executed formal documentation.

      The Loan Agreement is subject to certain requirements that the Company
make mandatory prepayments of the Augustine Loan from the proceeds of any asset
sales outside of the ordinary course of business, and, on a quarterly basis,
from positive cash flow. In addition, the Company may prepay all or any portion
of the Augustine Loan at any time without premium or penalty. The proceeds of
the Augustine Loan were used by the Company for working capital. As security for
the Augustine Loan, New Millennium (an affiliate of Mr. Calvert) pledged 2.5
million shares of the Company's common stock owned by New Millennium, and the
Company has granted Augustine Fund a security interest in its ownership interest
in the Company's subsidiary, NuWay Sports, LLC.

      The Company recorded interest expense of $72,478 for the year ended
December 31, 2005 and $69,445 for the year ended December 31, 2004.

                                       F-19
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      Using the Black-Scholes pricing model, the Company allocated approximately
$245,000 of the Augustine Loan proceeds to the warrants and $175,000 to the note
payable, which allocations were made on a pro rata basis based on the fair value
of the warrants. The Black Scholes calculation assumed a discount rate of
approximately four percent, volatility of 257 percent and no dividends. Given
that the warrants were issued in conjunction with Loan Agreement, such fair
value represents an effective discount on the debt and will be amortized over
the term of the loan. Amortization of this discount for the year ended December
31, 2005 was approximately $0 and $61,500 for the years ended December 31, 2005
and 2004 and is recorded as additional interest expense in the accompanying
consolidated statement of operations. In conjunction with the extension of the
maturity date of the Augustine Loan from February 2004 to August 2004, the
warrants held by Augustine Fund to purchase 6,158,381 shares of the Company's
common stock were re-priced to an exercise price of $.035 per share.

      As of December 31, 2005, the principal amount of the loan of $420,000,
together with approximately $165,256 in accrued but unpaid interest, had not
been repaid.



NOTE 9. OTHER LOAN


      On November 20, 2003, the Company received $50,000 in exchange for a
promissory note in which it agreed to pay $65,000 to Dr. James Seay 90 days from
the date of the loan. The Company's president personally guaranteed the note.
The note matured on February 18, 2004. The Company has paid Dr. Seay $30,000 and
the balance of $35,000 remains outstanding. On February 10, 2005, the Company
amended its obligations to Dr. Seay, which amendment (i) extends the maturity
date of the note to February 3, 2006, (ii) provides for interest to accrue at a
rate of 10% per annum (15% upon default), and (iii) allows for the conversion of
the note into 7,000,000 shares of the Company's common stock, or $.005 per
share. In February 2006, this note has been further extended to the sooner of
June 30, 2006, or the date the Company's stockholders approve an amended to the
Company's charter increasing the number of authorized shares of common stock.



NOTE 10. RELATED PARTY TRANSACTIONS


      NEW MILLENNIUM

      In conjunction with the acquisition from Med Wireless of the license for
the Med Wireless and PRLS technologies on August 21, 2002, the Company assumed a
$1,120,000 note (the "Med Wireless Note") with interest at 10% per annum payable
by Med Wireless to Summitt Ventures, Inc. ("Summitt Ventures"). Summitt Ventures
is controlled by Mark Anderson, a former consultant and principal stockholder of
the Company. The Med Wireless Note is secured by the Company's assets and was
originally due on June 15, 2003.

                                       F-20
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      As part of a series of transactions that the Company undertook to separate
itself completely from Mr. Anderson, on March 26, 2003, Summitt Ventures sold
the Med Wireless Note, together with 4,182,107 shares of the Company's common
stock owned by Mr. Anderson's affiliates, Camden Holdings and Summit Healthcare,
to New Millennium, in exchange for a $900,000 promissory note issued by New
Millennium in favor of Summitt Ventures, Camden Holdings, and Summit Healthcare
(the "New Millennium Note"). The New Millennium Note is secured by all of the
stock of the Company owned by New Millennium and Mr. Calvert. (See "Augustine
Fund Note" above.) Other than Mr. Calvert, no individual, entity or party
presently or previously associated with the Company has ever had any ownership
interest in New Millennium. Mr. Anderson, a principal of those companies that
sold and/or licensed the technologies to the Company, conditioned the
transaction with New Millennium on the Company's agreeing to convert the Note to
common stock.

      Since New Millennium purchased the Med Wireless Note, the Company has
attempted multiple times to convert the note, but has been unable to obtain the
required stockholder vote, due to a lack of quorum, to do so. The three attempts
are described below.

      On March 26, 2003, the Company's board of directors voted to convert the
Med Wireless Note into 22,400,000 shares of common stock of the Company, at a
conversion price discounted 37.5% from the then market price of $0.08. New
Millennium agreed to this conversion.

      In arriving at a conversion price, the board of directors determined that
a 37.5% discount to market price was appropriate based on a number of factors,
including that (i) with the quantity of the shares that would be issued, a block
of shares that size could not be liquidated without affecting the market price
of the shares, and (ii) the shares would be "restricted shares" and could
therefore not be sold by New Millennium in the public markets prior to two years
from the date of the conversion, and thereafter would be subject to the volume
and manner of sale limitations of Rule 144 under the Securities Act of 1933.

      Subsequent to the vote by the board to convert the Med Wireless Note, the
Company received notification from NASDAQ's Listing Qualifications Department
that converting the Note without stockholder approval violated certain NASDAQ
Marketplace Rules. In response to this notification, the board, with the
concurrence of New Millennium, voted to amend its resolution and delay
conversion of the Note until the Company's stockholders approved the conversion.

      At the Company's June 6, 2003 board meeting, Mr. Calvert, on behalf of New
Millennium, and the Company, through the unanimous action of the board (with Mr.
Calvert abstaining), agreed that, in light of current market conditions (namely
the significant increase in the trading price of the Company's common stock
since March 26, 2003, the date on which the conversion of the Med Wireless Note
was originally approved by the board, from $0.08 to $0.28 as of June 6, 2003),
it would be inequitable for New Millennium to convert the note at the originally
agreed to $0.05 per share price. Mr. Calvert, on behalf of New Millennium, and
the Company orally agreed to rescind the agreement to convert the note.

                                       F-21
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      In addition, New Millennium orally agreed with the Company to extend the
maturity date of the Med Wireless Note to a first payment due October 1, 2003 in
the amount of $100,000 and the balance of the principal due on April 1, 2004,
with interest due according to the original terms of the note (to correspond to
the payment terms of the New Millennium Note), and furthermore to reduce the
Company's obligation on the note to the extent that New Millennium might be able
to reduce its obligation on the New Millennium Note. While the prior holder of
the Med Wireless Note, Summitt Ventures, purported to condition New Millennium's
purchase on the conversion of the Med Wireless Note, Mr. Calvert has represented
to the Company that due to Mr. Anderson's failure to honor his obligations in
the purchase agreement, Mr. Calvert now believes that conversion of the Med
Wireless Note is no longer a required term of the agreement between New
Millennium and Summitt Ventures.

      The Company was unable to make the $100,000 payment on the Med Wireless
Note on the extended due date of October 1, 2003. At a board meeting on October
15, 2003, the board decided to put the issue of conversion of the note to the
Company's stockholders at a special meeting of the stockholders scheduled for
December 9, 2003. The stockholders meeting was held on December 9, 2003, but
adjourned without a vote, because not enough shares to constitute a quorum were
represented. The stockholders meeting was rescheduled for December 30, 2003, at
which a quorum was also not present. Because this was the second attempt to
obtain a quorum, and more than 4,000,000 additional shares were required to be
voted to obtain a quorum, the board adjourned the meeting indefinitely. As a
result, the Med Wireless Note was not converted into stock and the outstanding
principal amount, together with accrued and unpaid interest, remains as a
liability of the Company.

      In conjunction with the Company's January 31, 2004 purchase of Premium
Medical Group, Inc., a Florida corporation ("PMG"), later rescinded in October
2004, (see Note 13), and as a condition to that transaction (the "PMG
Transaction"), the Premium Medical Group shareholders (the "PMG Shareholders")
required the Company to convert the Med Wireless Note so as to eliminate the
obligation from the Company's balance sheet. At a meeting on February 10, 2004,
the board of directors voted to convert the note into 30,869,992 shares of its
common stock, at a conversion price of $0.04, discounted 20% from the then
market price of $0.05. New Millennium agreed to this conversion. In arriving at
a conversion price, the board of directors determined that a 20% discount to
market price was appropriate based on a number of factors, including (i) the
holding period of the stock will be two years, and thus is not liquid until that
point, and (ii) the amount of the stock issued would make it impossible to
liquidate the stock at the current market price. This discount was equal to the
discount proposed to the stockholders in December 2003 at the abandoned
stockholders meeting, and less than the discount used by the board at the first
conversion attempt in April 2003.

                                       F-22
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The board approved the conversion knowing that, since its conversion was a
condition imposed by the PMG Shareholders, they (who would hold 45% of the
Company's common stock at the time of such meeting) would provide the additional
shares necessary to obtain a quorum and formal stockholder approval. Stockholder
approval was also necessary to increase the number of authorized shares
necessary to convert the Med Wireless Note. However, due to lack of operational
capital, the Company was unable to remain current in its SEC filings, and thus
was unable to hold the required stockholder meeting.

      In October 2004, the Company, PMG and the PMG Shareholders rescinded the
PMG Transaction. Because the board of director's decision to convert the Med
Wireless Note was based in part on the requirements of the PMG Shareholders, the
board on October 28, 2004, determined not to convert the Note. Considering that
the Company at the time was a shell corporation with no operations, Mr. Calvert
also agreed to extend the maturity of the Med Wireless Note indefinitely until
the Company's status changed.

      Accordingly, as of December 31, 2005, the principal amount of the Med
Wireless Note, together with $317,956 in accrued but unpaid interest, had not
been repaid.

      Under the terms of the New Millennium Note, it is possible that Summitt
Ventures, Camden Holdings and Summit Healthcare may have a claim to reacquire
the shares of the Company's common stock that were sold to New Millennium. The
New Millennium Note is purportedly secured by the purchased shares of the
Company's common stock; however, New Millennium and Mr. Calvert believe that Mr.
Anderson and his affiliates have not perfected their security interest in those
shares. In addition, the Augustine Fund is the pledgee of 2,500,000 of these
shares and has physical possession of those shares.

      Mr. Calvert has proposed to the Board of Directors a plan to amend the New
Millennium Note to extend the due date to January 15, 2008; waive any cash
payments of interest until the New Millennium Note becomes due; reduce the
principal amount of the New Millennium Note from $1,120,000 to $900,000, equal
to a 19.6% reduction; and comparably reduce the accrued but unpaid interest due
under the terms of the New Millennium Note from $317,956 to $255,636, also equal
to a 19.6% reduction. The proposal is currently under consideration by the Board
of Directors.

      OBLIGATIONS TO DENNIS CALVERT

      In 2003 and 2004, the Company's President, Dennis Calvert, loaned money to
the Company by paying from his personal funds certain of the Company's expenses.
A significant portion of these personal funds was obtained by Mr. Calvert by
refinancing his primary residence and cashing out equity thereon. On March 7,
2005, the Company and Mr. Calvert agreed that the $101,770 still outstanding and
owed by the Company to Mr. Calvert would be repaid under the terms of a
promissory note bearing interest of 10% per annum, requiring monthly payments
and maturing on January 15, 2006. As of December 31, 2005, the Company had
repaid approximately $92,800 of this loan; approximately $9,000 principle
remained outstanding. Subsequent to the end of the fiscal year ended December
31, 2005, the balance of this obligation was repaid by the Company.

                                       F-23
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      As of December 31, 2005, the Company had accrued an expense related to the
unpaid accrued compensation due Mr. Calvert in the amount of $328,821.

      The Company currently occupies space from a consultant at no cost to the
Company.



NOTE 11. PROVISION FOR INCOME TAXES


      Any deferred tax assets have been subjected to a 100% valuation allowance,
as management is unable to determine that it is more likely than not that such
will be realized. Due to changes in the Company's ownership through various
issuance of common stock during 2002 and 2003, the utilization of net operating
loss carryforwards may be subjected to annual limitations under provisions of
the Internal Revenue Code. Such limitations could result in the permanent loss
of a portion of the net operating loss carry forwards. The Company has not yet
evaluated the status of its net operating loss carry forwards and may not do so
until such time as the Company expects operating profits.

      The Company has not filed its 2002, 2003 and 2004 Federal and State Income
tax returns. Management of the Company does not feel that it will have a
material impact on the financial condition of the Company.



NOTE 12. COMMITMENTS AND CONTINGENCIES



      LITIGATION

      In June 2002, Geraldine Lyons, the Company's former Chief Financial
Officer, sued the Company and the Company's former president Todd Sanders, for
breach of her employment contract. The lawsuit was brought in the Circuit Court
of the 11th Judicial Circuit in Miami-Dade County in Florida. Ms. Lyons seeks
approximately $25,000 due under the contract and the issuance of 100,000 shares
of common stock, with a guarantee that the stock could be sold by Ms. Lyons for
$300,000. Ms. Lyons alleges that additional funds are due under her employment
contract; that the contract requires the Company guarantee that she can sell for
$300,000 the 100,000 shares of stock the Company is required to issue her; and,
that Mr. Sanders promised to purchase from her 100,000 shares of Company common
stock held by her at the price of $4.00 per share.

                                       F-24
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The Company has counter-sued Ms. Lyons for breach of fiduciary duty,
fraud, violation of Section 12(a)(2) of the Securities Act of 1933, violation of
Section 517.301 of the Florida Statutes, negligent misrepresentation, conversion
and unjust enrichment resulting from the required restatement of the Company's
financial statements for the years ended December 31, 2000 and December 31,
1999. The restatements corrected the previous omission of certain material
expenses related primarily to compensation expense arising from warrants issued
and repriced stock options, as well as other errors.

      The case is ongoing at this time, although it has not been vigorously
prosecuted by Ms. Lyons or the Company, in the Company's case primarily because
the Company had lacked the resources to do so. The Company entered into an
agreement ("Legal Defense Agreement") in December 2004 such that Augustine Fund
would pay for the legal expenses associated with the Company's defense and
affirmative claims in this lawsuit (with the right to withdraw funding at any
time), and in exchange would share any net proceeds awarded to the Company
pursuant to a settlement or judgment. The sharing arrangement provides that
Augustine Fund will recover first, out of any money available from recovery, its
legal and out of pocket expenses related to the lawsuit; second, 85% of any
additional amounts recovered up to $500,000; and third, 50% of amounts recovered
beyond $500,000. While the Company believes that it has meritorious positions in
this litigation, given the inherent nature of litigation, it is not possible to
predict the outcome of this litigation or the impact it would have on the
Company.

      In May 2004, the Company was sued by Flight Options, Inc. ("Flight
Options"), a jet plane leasing company, in the Superior Court of Orange County
California. The lawsuit alleges that the Company owes Flight Options
approximately $418,300, pursuant to a five-year lease assigned to the Company by
the Company's former president Todd Sanders, from his corporation, Devenshire
Management Corporation ("Devenshire"). Management of the Company believes that
the assignment of the lease was not properly authorized or approved by the
Company, and that by Mr. Sander's failure to identify the lease in a December
2002 settlement agreement with the Company, he breached the terms of that
settlement agreement and, pursuant to the settlement agreement, must indemnify
the Company for any losses owed to Flight Options. The Company filed a
cross-complaint against Mr. Sanders and Devenshire seeking indemnity and
alleging Mr. Sander's breached his fiduciary duties in connection with the
assignment of the lease. The Company's Legal Defense Agreement with the
Augustine Fund applies also to the Flight Options litigation.

      On March 17, 2005, the Company settled with Flight Options pursuant to a
stipulation that would have allowed the Company to pay Flight Options $100,000
on or before August 5, 2005; if $100,000 was not paid by August 5, 2005, Flight
Options could file a judgment against the Company for $163,310. The Company did
not make a payment on or before August 5, 2005. Subsequently, the parties agreed
that the Company would pay Flight Options a total of $116,000, which amount was
paid. In exchange, Flight Options dismissed the case.

                                       F-25
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      At about the time of the settlement with Flight Options, the Company, Mr.
Sanders and Devenshire agreed to submit the matters in the cross-complaint,
including the indemnity claim, to binding arbitration. On March 7, 2006, an
arbitrator issued an binding award in favor of the Company and against Mr.
Sanders for $120,000.

      Legal Fees in the matter have been paid by Augustine, pursuant to the
Legal Defense Agreement between Augustine and the Company. In January 2006,
Augustine and the Company agreed to modify the terms of the Legal Defense
Agreement to allow for both parties to share in any amounts which might be
recovered from Sanders, on a percentage basis equal to the respective costs
incurred by each party. Legal Fees incurred by Augustine are estimated to be
approximately $81,000 as of February 2006, but will likely increase.

      On December 4, 2004, the Company was sued by the law firm of Enenstein
Russell and Saltz, LLP to collect fees that had been billed to the Company in
the amount of $15,233, which had been disputed by the Company. In August of
2005, the Company settled the lawsuit for $9,000. The Company paid the
settlement and the law firm dismissed the lawsuit.

      The Company is party to various other claims, legal actions and complaints
arising periodically in the ordinary course of business. In the opinion of
management, no such matters will have a material adverse effect on the Company's
financial position or results of operations.

      EMPLOYMENT AGREEMENTS

      In January 1997, the Company entered into a five year employment agreement
with Lloyd Lyons, which provided in part that in the event of a merger,
consolidation, sale or conveyance of substantially all the assets of the Company
which resulted in the discharge of Mr. Lyons, he would be entitled to 200
percent of the balance of payments remaining under the contract. The contract
provided salary continuation for a period of two years after his death. In
January 2000, Mr. Lyons passed away and effective August 2, 2000 the Company
amended its employment contract with his widow and primary beneficiary of his
estate, whereby the salary continuation clause included in his contract was
replaced with a severance arrangement that requires the Company to pay Mrs.
Lyons $100,000 over a one year period commencing on the first month following
the termination of her employment with the Company. Furthermore, upon her
termination she is to receive 100,000 shares of common stock pursuant to an
amendment to her employment agreement. The amended employment agreement will
obligate the Company to register these shares and reimburse her for the
difference in the gross proceeds upon the sale of such shares and $300,000;
regardless of the time she holds such shares. Effective October 29, 2001 Mrs.
Lyons tendered her resignation and based upon the terms of her severance
agreement, expenses of $350,000 had been recorded of which $308,000 is included
in accounts payable and accrued expenses at December 31, 2004 and 2005.

                                       F-26
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      In December of 2002, The Company entered into a five-year employment
agreement with the Company's current president, Dennis Calvert. His agreement
calls for a base monthly income of $14,000 plus performance bonuses and employee
related benefits. He serves as president, Chief Executive Officer, Interim CFO
and Chairman of the Board.

      In March 2003, the Company entered into a five-year employment agreement
with Joseph Provenzano. Mr. Provenzano serves the Company as Secretary, Board
Member and Senior Executive reporting to Mr. Calvert. His agreement calls for
him to receive not less than $10,900 per month in salary plus incentive bonuses,
stock ownership participation and employee related benefits. At the Company's
discretion, the Company may choose to pay up to $4,900 of this monthly salary
with stock in lieu of cash. In 2005, the Company and Mr. Provenzano agreed that
he would work for the Company on an as needed basis. In 2005, the Company
accrued and paid Mr. Provenzano $39,900 for services performed.


      STOCK-BASED COMMITMENTS

      The Company has utilized the services of a number of consultants who were
compensated with shares of common stock. While each agreement can generally be
terminated with a 15-day notice, the Company may be obligated to issue
additional shares to the consultants.



NOTE 13. ABANDONED ACQUISITION


      On January 31, 2004, the Company entered into a Stock Purchase Agreement
(the "Stock Purchase Agreement") with PMG and the PMG Shareholders. Prior to
this transaction, there was no business or other relationship between the
Company and its affiliates and PMG or the PMG Shareholders.

      Pursuant to the Stock Purchase Agreement, the Company agreed to acquire
100% of the shares of PMG from the PMG Shareholders in exchange for 30,000,000
shares of the Company's common stock, subject to certain adjustments. The exact
number of Company Shares to be issued to the PMG Shareholders was subject to
adjustment in the event certain revenue was generated by PMG during one year
following the closing of the transaction. PMG had been organized in June 2003 to
provide medical products to hospitals and medical clinics in South America,
primarily Venezuela. One of the PMG Shareholders (Luis A. Ruiz) became a
director of the Company in connection with the transaction.

      The parties had a difference in expectations regarding who would be
ultimately responsible for paying for the audit of PMG that was required in
order for the Company to complete its disclosure obligations under the
Securities Exchange Act. Additionally, the Company did not have a sufficient
number of authorized and unissued shares of its common stock to both satisfy its
obligations to the PMG Shareholders and to issue shares of common stock in a
meaningful financing transaction, given the low price per share at which the
Company's common stock trades. The Company lacked the financial resources to
schedule a stockholders' meeting, prepare a proxy statement and solicit proxies
for the purpose of amending its Certificate of Incorporation to increase its
authorized capital stock. As a result of these and other factors, the Company
and PMG never consolidated their operations, the Company never exercised control
over PMG or its operations and the parties never exchanged stock certificates
evidencing their ownership in each other.

                                      F-27
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      Therefore, the parties entered into discussions and concluded amicably
that it was in the mutual best interest of the respective companies and their
respective stockholders, to rescind the transactions provided for in the Stock
Purchase Agreement and return all parties to their respective positions prior to
the transactions contemplated in the Stock Purchase Agreement.

      The parties entered into a Rescission Agreement on October 14, 2004 that
provides, in relevant part, that (i) all transactions contemplated by the Stock
Purchase Agreement shall be rescinded as if the Stock Purchase Agreement had
never been executed and delivered; (ii) the parties forever waive all rights to
receive stock in PMG and the Company, as the case may be; (iii) Luis A. Ruiz
shall resign as a director of the Company; and (iv) the Company and PMG shall
file appropriate documents with the Secretary of State of the State of Florida
with respect to the rescission of the exchange of shares provided for in the
Stock Purchase Agreement.



NOTE 14. RETIREMENT OF TREASURY STOCK


      During 2004, the Company determined that based on reconciliations of its
stock records and its stock transfer agent that 200,000 shares of the Company's
common stock has been issued in prior years but not recorded in the Company's
books. An adjustment was made as of December 31, 2004 to give effect to this
non-material error. In addition, the shares included in treasury stock were
determined to have been formally cancelled and an adjustment was made at
December 31, 2004 to reflect this cancellation.



NOTE 15. SUBSEQUENT EVENTS



      SALES OF UNREGISTERED SECURITIES

On March 6, 2006, the Company issued its Third Offering Notes in the aggregate
principal amount of $797,500, due and payable January 31, 2007, to 44 individual
investors. Each Third Offering Note bears interest at a rate of 10% per annum,
and can be converted, in whole or in part, into shares of the common stock of
the Company at an initial conversion price of $0.025 per share. Purchasers of
the Third Offering Notes also received, for no additional consideration, a Third
Offering Warrant entitling the holder to purchase a number of Shares of the
Company's Common Stock equal to the number of Shares of Common Stock into which
the Third Offering Note is convertible. The Third Offering Warrant is
exercisable at an initial exercise price of $0.05 per Share and expires on
January 31, 2008.

                                       F-28
<PAGE>
                        NUWAY MEDICAL, INC. AND SUBSIDARY
                          NOTES TO FINANCIAL STATEMENTS

      The Notes may not be converted by either the Company or the holder unless
and until each of the following events has first occurred: (i) the Company's
stockholders have approved an increase in the number of shares of common stock
authorized by the Company's Certificate of Incorporation in an amount not less
than the amount required to permit all the Notes and Warrants issued in this
series to be converted into shares of the Company's Common Stock and (ii) the
Company has filed with the Secretary of State of State of Delaware a Certificate
of Amendment to the Company's Certificate of Incorporation to amend its
Certificate of Incorporation to increase the number of shares of common stock
authorized by the Company's Certificate of Incorporation.

      This offering and the sales thereunder were made in reliance on the
exemption from registration contained in Section 4(2) of the Securities Act of
1933 and/or Regulation D promulgated thereunder as not involving a public
offering of securities.

      Until the Company's stockholders approve an amendment to the Company's
charter to increase the number of authorized shares of common stock, the Company
will be unable to fulfill its obligations to all convertible noteholders to
permit the conversion into common stock of amounts due pursuant to the terms of
the convertible notes. In the event that the Company has not raised further
capital prior to the maturity dates of the convertible notes, the Company would
be in default of those notes if its stockholders have not formally approved an
increase in the number of authorized common shares. The Company is not, at this
time, in default of the convertible notes.


                                       F-29